

# CITATION REPORT

List of articles citing

## Hypersensitivity reactions from taxol

DOI: 10.1200/jco.1990.8.7.1263

Journal of Clinical Oncology, 1990, 8, 1263-8.

**Source:** <https://exaly.com/paper-pdf/21224135/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1040	The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. <b>1991</b> , 52, 35-84		252
1039	THE IMPACT OF NATIONAL CANCER ACT. <b>1991</b> , 83, 1797-1797		11
1038	Allergic reactions to cytotoxic drugs--an update. <b>1992</b> , 3, 605-10		21
1037	The next generation: new chemotherapy agents for the 1990s. <b>1992</b> , 8, 83-94		2
1036	Experimental Chemotherapy. <b>1992</b> , 6, 927-940		4
1035	Taxol administered as a 120 hour infusion. <b>1992</b> , 10, 275-8		44
1034	New cytotoxic drugs and targets in oncology. <b>1992</b> , 14, 258-67		5
1033	Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. <b>1993</b> , 72, 2457-60		139
1032	Chapter 32. Taxol: From Discovery to Therapeutic Use. <b>1993</b> , 305-314		70
1031	An overview of experience with TAXOL (paclitaxel) in the U.S.A. <b>1993</b> , 19 Suppl C, 63-78		64
1030	Taxol and taxotere--current status and future prospects. <b>1993</b> , 29A, 1228-31		22
1029	A Knowledge-Intensive Genetic Algorithm for Supervised Learning. <b>1993</b> , 13, 189-228		135
1028	Steady-state plasma concentrations and effects of taxol for a 250 mg/m <sup>2</sup> dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. <b>1993</b> , 33, 48-52		51
1027	The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). <b>1993</b> , 19, 351-86		234
1026	Hypersensitivity reactions from taxol and etoposide. <b>1993</b> , 85, 2036		28
1025	Cancer of the ovary. <b>1993</b> , 329, 1550-9		313
1024	Coping with toxicities of docetaxel (Taxotere). <b>1993</b> , 4, 610-1		113

1023	Nursing implications in the administration of paclitaxel (TAXOL). <b>1993</b> , 9, 11-5		4
1022	Paclitaxel (TAXOL): side effects and patient education issues. <b>1993</b> , 9, 6-10		29
1021	Taxol in ovarian cancer. <b>1993</b> , 71, 1591-6		45
1020	Taxol: A New Antineoplastic Agent. <b>1993</b> , 16, 329-337		2
1019	Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer. <b>1993</b> , 4, 321-4		23
1018	Successful re-treatment with taxol after major hypersensitivity reactions. <i>Journal of Clinical Oncology</i> , <b>1993</b> , 11, 885-90	2.2	100
1017	Paclitaxel (Taxol) in Breast Cancer. <b>1994</b> , 8, 121-140		26
1016	Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. <b>1994</b> , 5, 827-33		16
1015	Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity?. <b>1994</b> , 5, 473-4		8
1014	Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. <b>1994</b> , 5, 185-7		27
1013	Tricuspid endocarditis induced by implantable venous access. <i>Journal of Clinical Oncology</i> , <b>1994</b> , 12, 1103-5		2
1012	Summary. <b>1994</b> , 28, S31-S34		1
1011	Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. <b>1994</b> , 24, 6-14		71
1010	Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. <b>1994</b> , 6, 40-8		55
1009	Cerebrovascular event following taxol infusion. <b>1994</b> , 6, 202-3		9
1008	A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study. <b>1994</b> , 12, 41-3		21
1007	Solvent- and concentration-dependent molecular interactions of taxol (Paclitaxel). <i>Journal of Pharmaceutical Sciences</i> , <b>1994</b> , 83, 1470-6	3.9	49
1006	New chemotherapeutic agents for breast cancer. <b>1994</b> , 74, 1164-76		17

1005	Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules. <b>1994</b> , 74, 1377-82	46
1004	Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. <b>1994</b> , 74, 1891-8	18
1003	Chemistry and Biology of Taxol. <b>1994</b> , 33, 15-44	526
1002	Chemie und Biologie von Taxol. <b>1994</b> , 106, 38-69	104
1001	Ein wasserlösliches Prodrug von Taxol mit der Fähigkeit zur Selbstorganisation. <b>1994</b> , 106, 1672-1675	9
1000	Taxol: the chemistry and structure-activity relationships of a novel anticancer agent. <b>1994</b> , 12, 222-7	131
999	Novel taxol formulations: preparation and characterization of taxol-containing liposomes. <b>1994</b> , 11, 889-96	172
998	How to make taxol from scratch. <b>1994</b> , 367, 593-4	43
997	Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study. <b>1994</b> , 70, 376-9	19
996	Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. <b>1994</b> , 85, 1057-62	19
995	Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. <b>1994</b> , 48, 794-847	295
994	Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. <b>1994</b> , 35, 121-6	13
993	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. <b>1994</b> , 34, 266-9	30
992	The Total Synthesis of Paclitaxel by Assembly of the Ring System. <b>1994</b> , 302-312	1
991	Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. <b>1994</b> , 69, 341-5	51
990	Cutaneous drug reactions. <b>1994</b> , 6, 83-122	9
989	Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1. <b>1994</b> , 5, 474	6
988	Current Status of Clinical Trials with Paclitaxel and Docetaxel. <b>1994</b> , 31-57	18

987	Pharmacology and Antitumor Effect of Novel Paclitaxel Formulations. <b>1994</b> , 111-123		7
986	Paclitaxel (taxol). <b>1994</b> , 14, 3-34		77
985	Paclitaxel-induced severe hypersensitivity reaction occurring as a late toxicity. <b>1995</b> , 6, 852		9
984	Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. <i>Journal of Pharmaceutical Sciences</i> , <b>1995</b> , 84, 1223-30	3.9	141
983	Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. <i>Journal of Pharmaceutical Sciences</i> , <b>1995</b> , 84, 1400-4	3.9	38
982	Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. <b>1995</b> , 13, 223-7		20
981	Current status of paclitaxel in the treatment of breast cancer. <b>1995</b> , 33, 27-37		24
980	Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. <b>1995</b> , 86, 1203-9		64
979	Approach To Complications Of Anti-Cancer Therapy In Emergency Practice. <b>1995</b> , 5, 61-76		4
978	Perianal Paget disease: a case report. <b>1995</b> , 6, 851-2		
977	Anaphylactoid reactions with intraperitoneal cisplatin. <b>1995</b> , 29, 260-3		6
976	Theoretical and practical aspects of paclitaxel scheduling. <b>1995</b> , 6, 861-3		9
975	Paclitaxel: Infusion Duration Effect on Toxicity and Efficacy. <b>1995</b> , 2, 107327489500200		1
974	Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. <b>1995</b> , 87, 1169-75		122
973	Significant hypersensitivity with paclitaxel managed by a 50 hour infusion. <i>Journal of Oncology Pharmacy Practice</i> , <b>1995</b> , 1, 47-50	1.7	
972	Paclitaxel (taxol). <b>1995</b> , 332, 1004-14		1703
971	Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. <b>1995</b> , 25, 337-43		7
970	Taxanes: a new class of antitumor agents. <b>1995</b> , 13, 381-404		218

969	Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. <b>1995</b> , 36, 227-232	9
968	Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. <b>1995</b> , 36, 107-14	50
967	Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). <b>1995</b> , 88, 73-9	83
966	Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. <b>1995</b> , 12 Suppl 1, S163-72	33
965	Successful parenteral desensitization to paclitaxel. <b>1996</b> , 97, 42-6	94
964	Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. <b>1996</b> , 107, 265-72	66
963	Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption. <b>1996</b> , 34, 313-4	32
962	PEG Modified Anticancer Drugs: Synthesis and Biological Activity. <b>1996</b> , 11, 122-134	17
961	Adverse drug events related to dosage forms and delivery systems. <b>1996</b> , 14, 39-67	19
960	Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel. <b>1996</b> , 124, 278	11
959	Burkholderia cepacia and nebulized albuterol. <b>1996</b> , 124, 274	
958	Infection Risks to Patients from HIV-Infected Health Care Workers. <b>1996</b> , 124, 277	
957	Interferon for chronic hepatitis B. <b>1996</b> , 124, 276-7	
956	Hemorrhagic proctosigmoiditis and Blastocystis hominis infection. <b>1996</b> , 124, 278-9	22
955	Safety profile of single-dose dexamethasone premedication for paclitaxel. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 2189-90	2.2 11
954	Health Values of the Seriously Ill. <b>1996</b> , 124, 279	1
953	Minibronchoalveolar Lavage by Respiratory Therapists. <b>1996</b> , 124, 275	
952	Pulmonary infiltrates following administration of paclitaxel. <b>1996</b> , 110, 289-92	55

951	Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. <b>1996</b> , 7, 978-9		36
950	Skin ulceration potential of paclitaxel in a mouse skin model in vivo. <b>1996</b> , 78, 152-6		25
949	Paclitaxel (Taxol)--a guide to administration. <b>1996</b> , 5, 147-52		10
948	A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. <b>1996</b> , 73, 210-6		71
947	Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review. <b>1996</b> , 22, 475-494		31
946	Paclitaxel-induced acute bilateral pneumonitis. <b>1997</b> , 31, 1471-4		43
945	Review : Pharmacokinetics and pharmacodynamics of the taxanes. <i>Journal of Oncology Pharmacy Practice</i> , <b>1997</b> , 3, 76-93	1.7	10
944	Review : Cremophor: Pharmacological activity of an "inert" solubiliser. <i>Journal of Oncology Pharmacy Practice</i> , <b>1997</b> , 3, 186-192	1.7	6
943	Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. <b>1997</b> , 54, 298-303		25
942	Paclitaxel formulation as a cause of ethanol intoxication. <b>1997</b> , 31, 873-5		12
941	Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. <b>1997</b> , 8, 611-4		70
940	The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. <b>1997</b> , 48, 353-74		585
939	Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel. <b>1997</b> , 14, 418-427		35
938	In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. <b>1997</b> , 33, 463-70		64
937	Nitric oxide and shock. <b>1997</b> , 43, 277-348		56
936	Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine. <b>1997</b> , 31, 1287-91		21
935	Methods for preventing reactions secondary to Cremophor EL. <b>1997</b> , 31, 1402-4		26
934	Liposomal delivery system for taxol. <b>1997</b> , 83, 87-90		20

933	In vitro and in vivo evaluation of taxol release from poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres. <b>1997</b> , 49, 157-166			50
932	Preparation, characterization and properties in vitro and in vivo of a paclitaxel- $\alpha$ albumin conjugate. <b>1997</b> , 47, 293-304			97
931	The administration of paclitaxel without prophylaxis for the prevention of hypersensitivity reactions: is this a rationale and safe therapeutic strategy?. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1997</b> , 123, 531-2	4.9		1
930	A feasibility study of 1-h paclitaxel infusion in patients with solid tumors. <b>1997</b> , 40, 353-7			12
929	Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. <b>1997</b> , 79, 1022-30			10
928	Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. <b>1997</b> , 71, 103-7			104
927	Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group. <b>1998</b> , 16, 183-90			12
926	Overview of recent topics in clinical pharmacology of anticancer agents. <b>1998</b> , 42 Suppl, S22-30			28
925	Taxol hypersensitivity: rapid retreatment is safe and cost effective. <b>1998</b> , 68, 25-8			42
924	Single-dose dexamethasone paclitaxel premedication. <b>1998</b> , 69, 122-4			36
923	CARDIAC COMPLICATIONS OF CANCER TREATMENT. <b>1998</b> , 16, 597-604			3
922	Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. <b>1998</b> , 255, 171-5			41
921	Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. <b>1998</b> , 261, 198-202			21
920	Schedule-dependent interaction of paclitaxel (Taxol) and irradiation in vitro. <b>1998</b> , 6, 10-7			4
919	Cytotoxicity of fractionated paclitaxel (Taxol) administration in vitro. <b>1998</b> , 174, 37-42			7
918	High-Dose Taxol, Cyclophosphamide, and Cisplatin with Stem Cell Support in the Treatment of Metastatic Breast Cancer. <b>1998</b> , 4, 165-170			
917	Pharmaceutical aspects of paclitaxel. <b>1998</b> , 172, 1-15			172
916	Chapter 13 History and Future Prospects of Camptothecin and Taxol. <b>1998</b> , 50, 509-536			8



915	Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. <b>1998</b> , 90, 300-6		286
914	Taxanes and other microtubule stabilising agents. <b>1998</b> , 8, 571-586		16
913	New active paclitaxel glucuronide derivative with improved water solubility.. <b>1998</b> , 12, 391		2
912	Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. <b>1998</b> , 12, 1035-40		31
911	Cytostatic drugs. <b>1998</b> , 21, 463-474		
910	Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. <b>1998</b> , 9, 573		24
909	Pneumocystis carinii pneumonia in breast cancer. <b>1998</b> , 9, 573-4		1
908	Clinical phase I study with one-hour paclitaxel infusion. <b>1998</b> , 9, 569-72		9
907	Clinical features of hypersensitivity reactions to carboplatin. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 1141-2.2		277
906	Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel. <i>Journal of Oncology Pharmacy Practice</i> , <b>1999</b> , 5, 83-86	1.7	2
905	Study on the formulation of o/w emulsion as carriers for lipophilic drugs. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>1999</b> , 15, 117-125	6	13
904	Effective desensitization protocol to paclitaxel following hypersensitivity reaction. <b>1999</b> , 9, 156-159		14
903	Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. <b>1999</b> , 72, 100-1		34
902	Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. <b>1999</b> , 54, 165-71		2
901	Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group. <b>1999</b> , 55, 91-6		9
900	Visualization and comparison of drug effects after local paclitaxel delivery with different catheter types. <b>1999</b> , 94, 454-63		13
899	An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1999</b> , 125, 427-9	4.9	51
898	Mucocutaneous reactions to chemotherapy. <b>1999</b> , 40, 367-98; quiz 399-400		240

897	Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. <b>1999</b> , 40, 67-74		13
896	On the Weak Intrinsic Luminescence from Paclitaxel Dissolved in Nonelectrolyte Solvents. <b>1999</b> , 53, 991-999		2
895	Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. <b>1999</b> , 11, 407-9		22
894	Phase I and pharmacokinetic study of oral paclitaxel. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2468-75	2.2	74
893	Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 102-5	2.2	139
892	Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. <b>2000</b> , 11, 565-8		38
891	Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. <b>2000</b> , 11, 687-94		8
890	Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. <b>2000</b> , 44, 156-63		52
889	Paclitaxel esters of malic acid as prodrugs with improved water solubility. <b>2000</b> , 8, 427-32		39
888	Possible drug-associated pancreatitis after paclitaxel-cremophor administration. <b>2000</b> , 20, 95-7		14
887	Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. <b>2000</b> , 63, 19-30		276
886	Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. <b>2000</b> , 63, 141-53		71
885	[Paclitaxel: a chemotherapeutic agent for prevention of restenosis? Experimental studies in vitro and in vivo]. <b>2000</b> , 89, 390-7		13
884	Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. <b>2000</b> , 46, 416-22		104
883	The pharmacokinetics of a 1-h paclitaxel infusion. <b>2000</b> , 45, 463-70		48
882	Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions. <b>2000</b> , 11, 899		2
881	Paclitaxel and Carboplatin (PC) Regimen for Advanced Non-Small-Cell Lung Cancer. <b>2000</b> , 35, 698-702		
880	Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients. <b>2000</b> , 39, 47-52		4

879	Molecular Microencapsulation: Paclitaxel Formations in Aqueous Medium Using Hydrophobized Poly(L-Lysine Citramide Imide). <b>2000</b> , 15, 99-114	8
878	Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.. <b>2000</b> , 16, 125	1
877	Application of lipid as emulsifier in the solvent evaporation technique in fabrication of polymeric nanospheres for controlled release of Taxol.	
876	Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. <b>2000</b> , 34, 1332-5	25
875	A differential scanning calorimetry study of phosphocholines mixed with paclitaxel and its bromoacylated taxanes. <b>2000</b> , 78, 246-56	67
874	Paclitaxel hypersensitivity reactions related to bee-sting allergy. <b>2000</b> , 355, 288-9	26
873	Synthesis of the C-13 side chain precursors of the 9-dihydrotaxane analogue ABT-271. <b>2000</b> , 2, 3627-30	7
872	Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. <b>2000</b> , 22, 263-302	468
871	Risks and benefits of taxanes in breast and ovarian cancer. <b>2000</b> , 23, 401-28	84
870	Prevention and management of antineoplastic-induced hypersensitivity reactions. <b>2001</b> , 24, 767-79	129
869	Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. <b>2001</b> , 84, 42-7	111
868	Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. <b>2001</b> , 1, 721-35	108
867	Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. <b>2001</b> , 37, 1590-8	1291
866	Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. <b>2001</b> , 24, 283-5	16
865	An efficient synthesis of the taxane-derived anticancer agent ABT-271. <b>2001</b> , 66, 3330-7	11
864	Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. <b>2001</b> , 12, 414-20	30
863	Using Acetylcysteine to Prevent Radiographic-Contrast-Media-Induced Nephropathy in a Patient with Chronic Renal Failure. <b>2001</b> , 36, 795-797	1
862	Cancer Chemotherapy Update: Paclitaxel and Cisplatin (TC) Regimen for Advanced Ovarian Cancer. <b>2001</b> , 36, 723-797	

861	Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2493-503	2.2	34
860	Famotidine: Prevention of Paclitaxel Hypersensitivity Reactions. <b>2001</b> , 36, 766-770		
859	Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. <b>2001</b> , 12, 1133-7		109
858	Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. <b>2001</b> , 91, 815-821		5
857	Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. <b>2001</b> , 92, 2592-602		128
856	Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. <b>2001</b> , 22, 251-61		18
855	Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. <b>2001</b> , 82, 550-8		101
854	Role of formulation vehicles in taxane pharmacology. <b>2001</b> , 19, 125-41		240
853	Oral delivery of taxanes. <b>2001</b> , 19, 155-62		131
852	Anaphylactoid reactions to vitamin K. <b>2001</b> , 11, 175-83		85
851	Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. <b>2001</b> , 71, 53-69		334
850	In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. <b>2001</b> , 72, 191-202		585
849	Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. <b>2001</b> , 61, 129-33		115
848	Prophylaxis for paclitaxel hypersensitivity reactions. <b>2001</b> , 35, 1114-7		31
847	Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. <b>2001</b> , 176, 718-20		27
846	Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients. <b>2002</b> , 22, 312-3		2
845	Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. <b>2002</b> , 106, 1195-8		114
844	Dexamethasone prophylaxis for paclitaxel hypersensitivity. <i>Journal of Oncology Pharmacy Practice</i> , <b>2002</b> , 8, 81-87	1.7	3

843	Implementation and results of a test dose program with taxanes. <b>2002</b> , 8, 337-41		3
842	Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. <b>2002</b> , 13, 767-75		21
841	Non-Sedating Antihistamines for Premedication in Ambulatory Oncology Patients. <b>2002</b> , 32, 108-109		2
840	Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyl dextran to create prodrugs. <b>2002</b> , 25, 632-41		44
839	Formulation development of a filter-sterilizable lipid emulsion for lipophilic KW-3902, a newly synthesized adenosine A1-receptor antagonist. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2002</b> , 50, 87-91	1.9	10
838	Cutaneous toxicities of cancer therapy. <b>2002</b> , 14, 212-6		97
837	A novel 2M(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. <b>2002</b> , 13, 1093-9		33
836	Premedication strategy for weekly paclitaxel. <b>2002</b> , 20, 666-72		35
835	Molecular Interactions between a Lipid and an Antineoplastic Drug Paclitaxel (Taxol) within the Lipid Monolayer at the Air/Water Interface. <b>2002</b> , 18, 4061-4070		49
834	Pilot study of hydrolytically activated paclitaxel prodrug therapy in patients with progressive malignancies. <b>2002</b> , 63, 247-262		6
833	An Acknowledgment. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2761-2761		2.2
832	Taxanes and Estramustine for Hormone-Refractory Prostate Cancer. <b>2002</b> , 37, 816-886		
831	Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2757-8	2.2	2
830	Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2760-1	2.2	22
829	The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 4276-8	2.2	16
828	Critical factors in optimizing graft-versus-leukemia effect for relapsed leukemias. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2756; author reply 2756-7	2.2	3
827	Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. <b>2002</b> , 83, 273-286		560
826	Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. <b>2002</b> , 54, 191-202		260

825	Epithelial ovarian cancer. <b>2002</b> , 3, 131-41	23
824	Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes. <b>2002</b> , 12, 1637-41	43
823	Paclitaxel and its formulations. <b>2002</b> , 235, 179-92	835
822	A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. <b>2002</b> , 84, 420-5	54
821	Pharmacokinetics of paclitaxel-containing liposomes in rats. <b>2003</b> , 5, E32	70
820	Kinetics of paclitaxel 2MN-methylpyridinium mesylate decomposition. <b>2003</b> , 4, E21	1
819	Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. <b>2003</b> , 20, 24-30	104
818	Managing taxane toxicities. <i>Supportive Care in Cancer</i> , <b>2003</b> , 11, 144-7	3.9 103
817	Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma. <b>2003</b> , 6, 243-9	7
816	A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. <b>2003</b> , 86, 93-100	110
815	Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. <b>2003</b> , 91, 417-29	191
814	Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. <b>2003</b> , 58, 4087-4114	278
813	Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. <b>2003</b> , 55, 707-12	46
812	Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. <b>2003</b> , 13, 355-60	50
811	Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. <b>2003</b> , 42, 665-85	457
810	Management of toxicities associated with the administration of taxanes. <b>2003</b> , 2, 141-6	49
809	Chapter 15 Endocytotic events versus particle size: Multi-disciplinary analyses demonstrate L.C.M. sizes are mostly submicron. <b>2003</b> , 255-316	
808	Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. <b>2003</b> , 14, 785-92	31

807	Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). <b>2003</b> , 13, 531-6		70
806	Taxanes in the adjuvant treatment of breast cancer. <b>2003</b> , 1, 222-31		
805	Role of sensory nerve peptides rather than mast cell histamine in paclitaxel hypersensitivity. <b>2004</b> , 169, 113-9		30
804	Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. <b>2004</b> , 11, 413-24		255
803	The Complement System. <b>2004</b> ,		6
802	Complement Activation-Related Pseudoallergy. <b>2004</b> , 361-396		3
801	Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. <b>2004</b> , 10, 3708-16		644
800	Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. <b>2004</b> , 17, 7-14		40
799	Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. <b>2004</b> , 109, 1558-63		28
798	Taxane-platinum combinations in advanced non-small cell lung cancer: a review. <b>2004</b> , 9 Suppl 2, 16-23		88
797	Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4523-31	2.2	110
796	Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. <b>2004</b> , 9, 829-36		76
795	Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. <b>2004</b> , 90, 304-5		104
794	Eosinophilic ascites: taxol-induced hypersensitivity?. <b>2004</b> , 15, 171-2		2
793	Design and evaluation of an emulsion vehicle for paclitaxel. I. Physicochemical properties and plasma stability. <b>2004</b> , 21, 1573-80		33
792	Study on surfactant coating of polymeric nanoparticles for controlled delivery of anticancer drug. <b>2004</b> , 283, 58-65		41
791	Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. <b>2004</b> , 112, 335-40		278
790	Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. <b>2004</b> , 286, 147-56		87

789	Fibrosis cutánea de miembros inferiores inducida por paclitaxel. <b>2004</b> , 95, 227-230	3
788	Similarity and difference in the acute lung injury induced by a radiographic contrast medium and an anticancer agent paclitaxel in rats. <b>2004</b> , 152, 27-34	2
787	CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. <b>2004</b> , 6 Suppl 2, S85-8	40
786	Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. <b>2004</b> , 10, 7677-84	192
785	Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. <b>2004</b> , 46, 888-94	12
784	Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel. <b>2004</b> , 15, 947-54	16
783	Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. <b>2005</b> , 16, 243-54	118
782	Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly( $\gamma$ -benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. <b>2005</b> , 296, 151-61	123
781	Paclitaxel interaction with phospholipid bilayers: high-sensitivity differential scanning calorimetric study. <b>2005</b> , 427, 175-180	11
780	Iron oxide nanoparticles for sustained delivery of anticancer agents. <b>2005</b> , 2, 194-205	730
779	Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment. <b>2005</b> , 101, 273-85	15
778	In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. <b>2005</b> , 104, 181-91	56
777	Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. <b>2005</b> , 109, 120-6	171
776	Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. <b>2005</b> , 96, 824-9	114
775	Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. <b>2005</b> , 99, 393-9	99
774	Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo. <b>2005</b> , 55, 47-54	21
773	Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. <b>2005</b> , 56, 91-6	23
772	Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. <b>2005</b> , 55, 565-76	79



771	Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. <b>2005</b> , 55, 497-501		28
770	[Skin changes with chemotherapy]. <b>2005</b> , 56, 591-602; quiz 603		2
769	Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. <b>2005</b> , 10, 333-7		10
768	Nebenwirkungen bei der Therapie des NSCLC aus der Sicht des Pneumologen. <b>2005</b> , 11, 40-44		4
767	Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. <b>2005</b> , 22, 573-83		114
766	Formulating paclitaxel in nanoparticles alters its disposition. <b>2005</b> , 22, 867-74		83
765	[Administration of taxane-containing drugs]. <b>2005</b> , 34, 152-8		
764	Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. <b>2005</b> , 5, 105-107		
763	Temperature- and pH-sensitive core-shell nanoparticles self-assembled from poly(n-isopropylacrylamide-co-acrylic acid-co-cholesteryl acrylate) for intracellular delivery of anticancer drugs. <b>2005</b> , 10, 3058-67		12
762	Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer. <b>2005</b> , 40, 310-314		
761	Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins. <b>2005</b> , 2, 443-9		27
760	Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 9120-9	2.2	93
759	Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). <b>2005</b> , 11, 4136-43		380
758	The role of taxanes in the treatment of breast cancer. <b>2005</b> , 6, 1073-94		34
757	NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. <b>2005</b> , 92, 1240-6		457
756	A randomized trial assessing the utility of a test-dose program with taxanes. <b>2005</b> , 21, 1611-6		6
755	Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7794-803	2.2	1618
754	Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6019-26	2.2	218

753	Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7785-93	2.2	239
752	Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. <b>2005</b> , 51, 116-9		11
751	Ovariectomy aggravates hypersensitivity reactions to paclitaxel in rats. <b>2005</b> , 4, 233-238		40
750	Feasibility studies of dermal delivery of paclitaxel with binary combinations of ethanol and isopropyl myristate: role of solubility, partitioning and lipid bilayer perturbation. <b>2005</b> , 60, 894-9		26
749	Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7768-71	2.2	80
748	Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. <b>2005</b> , 23, 671-6		36
747	Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2005</b> , 59, 177-87	5.7	252
746	Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. <b>2005</b> , 13, 73-80		151
745	Preparation and characterization of taxane-containing liposomes. <b>2005</b> , 391, 97-117		34
744	Thermally sensitive micelles self-assembled from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) for controlled delivery of paclitaxel. <b>2005</b> , 1, 158-65		64
743	Cardiotoxicity of cancer chemotherapy: implications for children. <b>2005</b> , 7, 187-202		118
742	Paclitaxel. <b>2006</b> , 2663-2669		
741	Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. <b>2006</b> , 6, 1249-69		61
740	Albumin-bound paclitaxel: a next-generation taxane. <b>2006</b> , 7, 1041-53		463
739	Emerging use of nanoparticles in diagnosis and treatment of breast cancer. <b>2006</b> , 7, 657-67		416
738	In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. <b>2006</b> , 7, 1139-46		72
737	Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. <b>2006</b> , 17, 1263-8		427
736	Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. <b>2006</b> , 42, 24-30		145

735	HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. <b>2006</b> , 24, 207-15	74
734	Anticancer Efficacy and Toxicity of Oral GMO-paclitaxel in a Hormone Refractory Prostate Cancer Model. <b>2006</b> , 47, 143	3
733	[Drug-induced lung diseases]. <b>2006</b> , 127, 425-32	5
732	Paclitaxel hypersensitivity reactions: assessment of the utility of a test-dose program. <b>2006</b> , 12, 237-45	9
731	Rapid desensitization for hypersensitivity reactions to chemotherapy agents. <b>2006</b> , 6, 271-7	36
730	Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. <b>2006</b> , 27, 747-53	78
729	NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. <b>2006</b> , 95, 601-6	77
728	Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. <b>2006</b> , 27, 262-70	196
727	In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. <b>2006</b> , 27, 2285-91	128
726	Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. <b>2006</b> , 315, 148-57	177
725	Suspected paclitaxel-induced pneumonitis. <b>2006</b> , 9, 325-8	14
724	Life-threatening adverse drug reaction to paclitaxel. Postmarketing surveillance. <b>2006</b> , 8, 60-1	3
723	Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. <b>2006</b> , 100, 149-51	30
722	Dermatologic toxicity of chemotherapeutic agents. <b>2006</b> , 33, 86-97	56
721	Novel agents that target tubulin and related elements. <b>2006</b> , 33, 421-35	60
720	New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment. <b>2006</b> , 33, S18-24	14
719	Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. <b>2006</b> , 118, 2636-8	15
718	Bioavailability of <sup>99m</sup> Tc-Ha-paclitaxel complex [ <sup>99m</sup> Tc-ONCOFID-P] in mice using four different administration routes. <b>2006</b> , 49, 939-950	16

717	Rapid desensitization of hypersensitivity reactions to chemotherapy agents. <b>2006</b> , 1, 243-51		26
716	Paclitaxel in breast cancer. <b>2006</b> , 2, 11-21		7
715	Carboplatin hypersensitivity reactions. <b>2006</b> , 10, 595-8		5
714	Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. <b>2006</b> , 103, 18356-61		96
713	Physical and chemical stability of paclitaxel infusions in different container types. <i>Journal of Oncology Pharmacy Practice</i> , <b>2006</b> , 12, 211-22	1.7	16
712	Novel formulations of taxanes: a review. Old wine in a new bottle?. <b>2006</b> , 17, 735-49		263
711	Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. <b>2006</b> , 12, 1317-24		878
710	PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. <b>2006</b> , 29, 444-50		4
709	Management and preparedness for infusion and hypersensitivity reactions. <b>2007</b> , 12, 601-9		335
708	Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. <b>2007</b> , 6, 3239-47		32
707	Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel. <b>2007</b> , 13, 3293-301		13
706	Novel Local Treatment with Paclitaxel-Loaded Hydroxyapatite-Alginate Gels for Spinal Bone Metastases. <b>2007</b> , 330-332, 1343-1346		6
705	Breast Cancer. <b>2007</b> ,		
704	Nanostructures for Cancer Diagnostics and Therapy. 409-437		2
703	Individualized pharmacotherapy with paclitaxel. <b>2007</b> , 19, 586-9		23
702	The artificial cell design: nanoparticles. <b>2007</b> , 103-114		
701	Highly active anticancer curcumin analogues. <b>2007</b> , 595, 77-103		107
700	Microtubule Protocols. <b>2007</b> ,		3

699	Prodrugs and Parenteral Drug Delivery. <b>2007</b> , 217-281	2
698	Assembling a mixed phthalocyanine-porphyrin array in aqueous media through host-guest interactions. <b>2007</b> , 9, 231-4	39
697	Nanosized paclitaxel particles from supercritical carbon dioxide processing and their biological evaluation. <b>2007</b> , 23, 2674-9	30
696	Paclitaxel: a review of adverse toxicities and novel delivery strategies. <b>2007</b> , 6, 609-21	281
695	Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. <b>2007</b> , 2, 333-44	45
694	Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles. <b>2007</b> , 15, 507-17	34
693	Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. <b>2007</b> , 13, 345-57	38
692	Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. <b>2007</b> , 2, 415-23	134
691	Albumin Nanoparticles. <b>2007</b> ,	2
690	Dexamethasone inhibits paclitaxel-induced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells. <b>2007</b> ,	2
689	. <b>2007</b> ,	21
688	PCL/poloxamer 188 blend microsphere for paclitaxel delivery: Influence of poloxamer 188 on morphology and drug release. <b>2007</b> , 104, 1895-1899	23
687	Synthesis, biological evaluations, and tubulin binding poses of C-2alpha sulfur linked taxol analogues. <b>2007</b> , 17, 3191-4	4
686	Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo. <b>2007</b> , 62, 6641-6648	71
685	A novel trans-lymphatic drug delivery system: implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres. <b>2007</b> , 28, 3236-44	75
684	Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. <b>2007</b> , 338, 317-26	312
683	A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. <b>2007</b> , 97, 170-6	235
682	Self-Assembled Poly(butadiene)-b-poly(ethylene oxide) Polymersomes as Paclitaxel Carriers. <b>2007</b> , 23, 278	8

681	A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. <b>2007</b> , 17, 367-72		8
680	Coronary stents, hypersensitivity reactions, and the Kounis syndrome. <b>2007</b> , 20, 314-23		64
679	A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future. <b>2007</b> , 105, 561-2		1
678	Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). <b>2007</b> , 117, 40-50		62
677	Novel drug-delivery strategies for the treatment of ovarian cancer. <b>2007</b> , 2, 587-593		
676	Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions. <b>2007</b> , 12, 274-8		6
675	In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. <b>2008</b> , 25, 1925-35		97
674	Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice. <b>2008</b> , 15, 99-109		12
673	Oral premedication for the prevention of hypersensitivity reactions to paclitaxel. <b>2008</b> , 25, 274-8		13
672	Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. <i>Journal of Pharmaceutical Sciences</i> , <b>2008</b> , 97, 1519-29	3-9	73
671	Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. <i>Journal of Pharmaceutical Sciences</i> , <b>2008</b> , 97, 3170-81	3-9	22
670	Feedback-regulated paclitaxel delivery based on poly(N,N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles. <b>2008</b> , 29, 1950-7		62
669	Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. <b>2008</b> , 347, 163-70		103
668	Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. <b>2008</b> , 359, 174-81		32
667	Protein nanoparticles as drug carriers in clinical medicine. <b>2008</b> , 60, 876-85		613
666	Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. <b>2008</b> , 60, 899-914		232
665	Generalized pustular dermatosis following paclitaxel therapy. <b>1997</b> , 36, 559-60		16
664	Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes. <b>2008</b> , 8 Suppl 2, S54-60		10

663	Options for the treatment of patients with taxane-refractory metastatic breast cancer. <b>2008</b> , 8 Suppl 2, S61-70		25
662	What is the role of novel taxanes in non-small-cell lung cancer?. <b>2008</b> , 9 Suppl 3, S116-21		4
661	Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan as a novel carrier for paclitaxel. <b>2008</b> , 19, 145101		55
660	Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. <b>2008</b> , 122, 574-80		374
659	A unique mode of microtubule stabilization induced by peloruside A. <b>2008</b> , 378, 1016-30		107
658	Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. <b>2008</b> , 46, 25-32		176
657	Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2008</b> , 70, 51-7	5-7	68
656	Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. <b>2008</b> , 197, 959-66		51
655	Conjugated chitosan as a novel platform for oral delivery of paclitaxel. <b>2008</b> , 51, 6442-9		128
654	Allergy diagnostic testing: an updated practice parameter. <b>2008</b> , 100, S1-148		475
653	Polymeric micellar delivery systems in oncology. <b>2008</b> , 38, 793-802		103
652	Large-bite bis(phosphite) ligand containing mesocyclic thioether moieties: synthesis, reactivity, group 11 (Cu(I), Au(I)) metal complexes and anticancer activity studies on a human cervical cancer (HeLa) cell line. <b>2008</b> , 2285-92		25
651	Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. <b>2008</b> , 34, 10-23		23
650	A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. <b>2008</b> , 14, 3598-606		77
649	Paclitaxel in the management of ovarian cancer. <b>2008</b> , 3, 287-299		
648	Taxanes in the management of gynecologic malignancies. <b>2008</b> , 8, 219-26		5
647	Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. <b>2008</b> , 14, 1510-8		31
646	Preparation of Water-Soluble Albumin Loaded Paclitaxil Nanoparticles Using Emulsion-Solvent Evaporation Technique. <b>2008</b> , 4, 51-55		4

645	Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. <b>2008</b> , 14, 5856-63		57
644	Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. <b>2008</b> , 19, 899-909		165
643	Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. <b>2008</b> ,		1
642	Clinical development of Abraxane, albumin-bound paclitaxel. <b>2009</b> , 24, 38-44		4
641	Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. <b>2009</b> , 4, 99-105		357
640	Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. <b>2009</b> , 20, 437-40		14
639	HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. <b>2009</b> , 3, 3165-74		142
638	Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3097-103	2.2	41
637	Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. <b>2009</b> , 133, 11-7		464
636	Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. <b>2009</b> , 140, 294-300		206
635	Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. <b>2009</b> , 140, 166-73		278
634	Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. <b>2009</b> , 38, 405-13		116
633	Stimuli-responsive polymersomes as nanocarriers for drug and gene delivery. <b>2009</b> , 9, 129-39		393
632	Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center. <i>Supportive Care in Cancer</i> , <b>2009</b> , 17, 1311-5	3.9	6
631	A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. <b>2009</b> , 30, 6006-16		185
630	Heparin-paclitaxel conjugates using mixed anhydride as intermediate: synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency. <b>2009</b> , 26, 785-93		18
629	Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process. <b>2009</b> , 32, 139-48		21
628	Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. <b>2009</b> , 63, 281-7		51



627	Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. <b>2009</b> , 63, 1049-63		40
626	Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. <b>2009</b> , 64, 87-94		15
625	Hierarchical supermolecular structures for sustained drug release. <b>2009</b> , 5, 1504-7		45
624	Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. <b>2009</b> , 100, 572-9		440
623	Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. <b>2009</b> , 100, 1979-85		49
622	Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer. <b>2009</b> , 5, 165-174		18
621	Morphology and in vitro release kinetics of drug-loaded micelles based on well-defined PMPC-b-PBMA copolymer. <b>2009</b> , 371, 190-6		41
620	Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. <b>2009</b> , 375, 170-6		95
619	Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. <b>2009</b> , 376, 176-85		312
618	Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2009</b> , 72, 9-17	5-7	75
617	Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. <b>2009</b> , 20, 2214-21		63
616	Simple approach to stabilized micelles employing miktoarm terpolymers and stereocomplexes with application in paclitaxel delivery. <b>2009</b> , 10, 1460-8		104
615	Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. <b>2009</b> , 45, 2132-7		16
614	Paclitaxel and vinorelbine, evoked the release of substance P from cultured rat dorsal root ganglion cells through different PKC isoform-sensitive ion channels. <b>2009</b> , 57, 25-32		28
613	Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. <b>2009</b> , 36, 525-33		21
612	Chapter 7 Paclitaxel. <b>2009</b> , 34, 299-344		8
611	Rapid desensitization for hypersensitivity reactions to medications. <i>Immunology and Allergy Clinics of North America</i> , <b>2009</b> , 29, 585-606	3-3	88
610	PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. <b>2009</b> , 6, 468-79		56

609	Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action. <b>2009</b> , 6, 132-134	24
608	Novel thermo-sensitive core-shell nanoparticles for targeted paclitaxel delivery. <b>2009</b> , 20, 065104	40
607	Manejo general y extrahospitalario del paciente en tratamiento con quimioterapia y de sus complicaciones. <b>2009</b> , 10, 1613-1618	
606	Natural compounds for cancer treatment and prevention. <b>2009</b> , 59, 365-78	464
605	Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. <b>2009</b> , 102, 179-87; quiz 187-9, 222	110
604	Chemotherapy and biotherapy-induced hypersensitivity reactions. <b>2009</b> , 32, 157-65	6
603	Paclitaxel-induced interstitial pneumonia after drug-eluting stent implantation: report of a fatal case. <b>2009</b> , 48, 911-3	3
602	Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. <b>2009</b> , 19, 1281-3	30
601	Recent patents reveal microtubules as persistent promising target for novel drug development for cancers. <b>2009</b> , 4, 164-82	9
600	A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. <b>2010</b> , 5, 852-61	62
599	Paclitaxel and Epothilone Analogues, Anticancer Drugs. <b>2010</b> , 243-267	2
598	Low Molecular Weight Water Soluble Chitosan with Free Amine Group for Drug Delivery. <b>2010</b> , 325-337	
597	Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. <b>2010</b> , 21, 415103	45
596	Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. <b>2010</b> , 11, 1413-32	83
595	Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel. <b>2010</b> , 31, 1765-72	118
594	Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice. <b>2010</b> , 27, 421-30	50
593	Drug delivery systems for intraperitoneal therapy. <b>2010</b> , 27, 735-8	73
592	The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency. <b>2010</b> , 27, 380-9	66

591	Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. <b>2010</b> , 27, 1498-511		57
590	Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. <b>2010</b> , 27, 2569-89		688
589	Non-ionic dendritic glycerol-based amphiphiles: novel excipients for the solubilization of poorly water-soluble anticancer drug Sagopilone. <b>2010</b> , 40, 48-55		19
588	Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation. <b>2010</b> , 53, 115-21		14
587	The effect of novel surfactants and Solutol HS 15 on paclitaxel aqueous solubility and permeability across a Caco-2 monolayer. <i>Journal of Pharmaceutical Sciences</i> , <b>2010</b> , 99, 3473-85	3.9	30
586	Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. <i>Journal of Pharmaceutical Sciences</i> , <b>2010</b> , 99, 4543-53	3.9	68
585	Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. <i>Journal of Pharmaceutical Sciences</i> , <b>2010</b> , 99, 4746-52	3.9	11
584	Disulfide-Crosslinked Biomimetic Micelles: Formation, Thiol Reactivity and Cytotoxicity Behavior. <b>2010</b> , 211, 2292-2300		23
583	Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly( $\epsilon$ -caprolactone) nanoparticles: In vitro and in vivo evaluation. <b>2010</b> , 402, 238-47		106
582	Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. <b>2010</b> , 31, 7106-14		123
581	Characterization and preparation of core-shell type nanoparticle for encapsulation of anticancer drug. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2010</b> , 81, 530-6	6	29
580	Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. <b>2010</b> , 76, 816-23		24
579	A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours. <b>2010</b> , 103, 1362-8		19
578	. <b>2010</b> ,		25
577	Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. <b>2010</b> , 332, 479-88		14
576	Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. <b>2010</b> , 21, 382-388		99
575	Novel drug delivery systems for sustained and targeted delivery of anti- cancer drugs: current status and future prospects. <b>2010</b> , 7, 152-61		44
574	nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. <b>2010</b> , 9, 515-23		13

573	The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. <b>2010</b> , 94, 835-52, xiii		47
572	Lipid-Based Anticancer Prodrugs. <b>2010</b> , 291-328		1
571	Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. <b>2010</b> , 9, 39-53		28
570	Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel. <b>2002</b> , 54, 765-72		39
569	Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. <b>2010</b> , 21, 1216-24		135
568	Polysaccharide-Based Anticancer Prodrugs. <b>2010</b> , 163-219		8
567	Delivering nanomedicine to solid tumors. <b>2010</b> , 7, 653-64		2279
566	Lung Cancer. <b>2010</b> , 183-211		
565	Solid Nanosuspensions: The Emerging Technology and Pharmaceutical Applications as Nanomedicine. <b>2010</b> , 285-318		7
564	Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2010</b> , 75, 341-53	5.7	151
563	Glioblastoma. <b>2010</b> ,		1
562	Characterization, in vitro cytotoxicity and cellular accumulation of paclitaxel-loaded lipid nano-emulsions. <b>2010</b> , 27, 453-9		7
561	Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. <b>2010</b> , 36, 1377-87		36
560	Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. <b>2010</b> , 28, 74-84		42
559	Albumin-Drug Nanoparticles. <b>2011</b> , 1133-1161		
558	Targeted Drug-Delivery Therapy of Tumors Using LCM. <b>2011</b> , 25, 189-205		
557	Recent developments in treatment stratification for metastatic breast cancer. <b>2011</b> , 71, 2099-113		10
556	Localized delivery of paclitaxel using elastic liposomes: formulation development and evaluation. <b>2011</b> , 18, 367-76		40

555	Macromolecules as taxane delivery systems. <b>2011</b> , 8, 33-55		12
554	A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). <b>1997</b> , 49, 16-21		73
553	Allergic reactions to chemotherapy. <b>2011</b> , 10-15		
552	A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. <b>2011</b> , 2, 153-64		9
551	Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. <b>2011</b> , 6, 1497-507		34
550	Negative Impact of Paclitaxel Crystallization on Hydrogels and Novel Approaches for Anticancer Drug Delivery Systems. <b>2011</b> ,		1
549	Novel free paclitaxel-loaded poly(L-Glutamylglutamine)-paclitaxel nanoparticles. <b>2011</b> , 6, 85-91		28
548	Paclitaxel loaded nanosponges: in-vitro characterization and cytotoxicity study on MCF-7 cell line culture. <b>2011</b> , 8, 194-202		45
547	Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice. <b>2011</b> , 113, 947-50		68
546	ONCOFID&#8482;-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis. <b>2011</b> , 7, 27-32		10
545	Formulation, characterization and hypersensitivity evaluation of an intravenous emulsion loaded with a paclitaxel-cholesterol complex. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2011</b> , 59, 321-6	1.9	17
544	Desensitization regimens for drug allergy: state of the art in the 21st century. <b>2011</b> , 41, 1679-89		85
543	Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties. <b>2011</b> , 78, 547-57		33
542	Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA--multi-armed PEG nanocapsules. <b>2011</b> , 32, 8635-44		42
541	Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. <b>2011</b> , 32, 9444-56		139
540	Cytostatic and cytotoxic drugs. <b>2011</b> , 33, 935-962		1
539	Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. <b>2011</b> , 12, 712-22		64
538	Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. <b>2011</b> , 63, 1020-30		301

537	Correlation between docetaxel-induced skin toxicity and the use of steroids and H <sub>2</sub> blockers: a multi-institution survey. <b>2011</b> , 130, 627-34	12
536	Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy. <b>2011</b> , 28, 675-88	10
535	Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98G cells. <b>2011</b> , 36, 2292-305	15
534	Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors. <b>2011</b> , 68, 971-8	15
533	Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts. <b>2011</b> , 403, 130-5	5
532	PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. <b>2011</b> , 412, 132-41	104
531	Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery. <b>2011</b> , 414, 161-70	110
530	Angiopep-conjugated poly(ethylene glycol)-co-poly( $\epsilon$ -caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. <b>2011</b> , 32, 4293-305	299
529	Integrin-targeted paclitaxel nanoliposomes for tumor therapy. <b>2011</b> , 28, 1180-7	34
528	Cross-sensitivity between taxanes in patients with breast cancer. <b>2011</b> , 13, 904-6	11
527	Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. <b>2011</b> , 34, 331-7	38
526	Methoxy poly(ethylene glycol)-b-poly(octadecanoic anhydride)-b-methoxy poly(ethylene glycol) amphiphilic triblock copolymer nanoparticles as delivery vehicles for paclitaxel. <b>2011</b> , 22, 669-674	1
525	Preparation and photodynamic activities of silicon(IV) phthalocyanines substituted with permethylated $\beta$ -cyclodextrins. <b>2011</b> , 17, 7569-77	57
524	Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. <b>2011</b> , 32, 2894-906	296
523	The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. <b>2011</b> , 32, 3285-302	133
522	An oil-free microemulsion for intravenous delivery of diallyl trisulfide: formulation and evaluation. <b>2011</b> , 407, 158-66	19
521	Preparation and characterization of polymeric pH-sensitive STEALTH $\square$ nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel. <b>2011</b> , 408, 208-12	23
520	Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. <b>2011</b> , 414, 251-9	66

519	Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. <b>2011</b> , 23, 59-66	55
518	A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. <b>2011</b> , 17, 3398-407	28
517	Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer. <b>2011</b> , 4, 186-91	18
516	Selected Parenteral Lipid Nanoemulsions Under Clinical Study. <b>2011</b> , 25, 247-254	
515	Paclitaxel and Bevacizumab Regimen for Metastatic Breast Cancer. <b>2011</b> , 46, 19-22	
514	A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety. <b>2011</b> , 2011, 854872	23
513	Agents that induce pseudo-allergic reaction. <b>2011</b> , 5, 211-9	29
512	Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. <b>2011</b> , 10, 521-8	23
511	Paclitaxel, Carboplatin, and Bevacizumab. <b>2011</b> , 46, 406-414	
510	Weekly Paclitaxel and Carboplatin for Non-Small-Cell Lung Cancer. <b>2011</b> , 46, 166-169	
509	Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study. <b>2011</b> , 43, 126-30	8
508	Ethyl gallate induces apoptosis of HL-60 cells by promoting the expression of caspases-8, -9, -3, apoptosis-inducing factor and endonuclease G. <b>2012</b> , 13, 11912-22	17
507	"OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. <b>2012</b> , 72, 2100-10	74
506	Successful desensitization to docetaxel after severe hypersensitivity reactions in two patients. <b>2012</b> , 69, 499-503	1
505	Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. <b>2012</b> , 2012, 623139	107
504	Carboplatin-induced hypersensitivity reaction. <b>2012</b> , 5, 141-2	1
503	Analogue-based drug discovery: Contributions to medicinal chemistry principles and drug design strategies. Microtubule stabilizers as a case in point (Special Topic Article). <b>2012</b> , 84, 1479-1542	8
502	Tumour-specific uptake of anti-cancer drugs: the future is here. <b>2012</b> , 13, 4-21	17

501	Nanodrug potential in cancer therapy: efficacy/toxicity studies in cancer cells. <b>2012</b> , 9, 502		3
500	Challenges in development of nanoparticle-based therapeutics. <b>2012</b> , 14, 282-95		514
499	Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. <b>2012</b> , 61, 1575-84		67
498	Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. <b>2012</b> , 29, 2833-44		21
497	Fatty acid-RGD peptide amphiphile micelles as potential paclitaxel delivery carriers to $\alpha v \beta 3$ integrin overexpressing tumors. <b>2012</b> , 29, 3347-61		28
496	Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. <b>2012</b> , 12, 313-21		89
495	Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. <b>2012</b> , 436, 135-40		17
494	Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles. <b>2012</b> , 9, 2302-13		96
493	Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation. <b>2012</b> , 19, 11-20		22
492	Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?. <i>Journal of Oncology Pharmacy Practice</i> , <b>2012</b> , 18, 250-6	1.7	20
491	Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases. <b>2012</b> , 26, 159-64		7
490	Desensitization for hypersensitivity reactions to medications. <b>2012</b> , 97, 217-33		23
489	Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study. <b>2012</b> , 3, 341-347		20
488	Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. <b>2012</b> , 13, 395-406		57
487	Nonallergic drug hypersensitivity reactions. <b>2012</b> , 159, 327-45		51
486	Self-assembled micelles of monosialogangliosides as nanodelivery vehicles for taxanes. <b>2012</b> , 162, 619-27		20
485	Liposomal paclitaxel formulations. <b>2012</b> , 163, 322-34		234
484	Paclitaxel-loaded polymeric micelles based on poly( $\epsilon$ -caprolactone)-poly(ethylene glycol)-poly( $\epsilon$ -caprolactone) triblock copolymers: in vitro and in vivo evaluation. <b>2012</b> , 8, 925-34		71



483	In vitro phototoxicity and dark-toxicity of a novel synthesized pyropheophorbide-a-paclitaxel conjugate against cancer cell lines. <b>2012</b> , 16, 1006-1014	3
482	Taxol, Camptothecin and Beyond for Cancer Therapy. <b>2012</b> , 133-178	3
481	Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites. <b>2012</b> , 4, 3095-104	99
480	Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. <b>2012</b> , 4, 6004-17	71
479	Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid micelles. <b>2012</b> , 7, 325-37	63
478	Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity. <b>2012</b> , 7, 1313-28	21
477	Development, Optimization and Absorption Mechanism of DHP107, Oral Paclitaxel Formulation for Single-Agent Anticancer Therapy. <b>2012</b> ,	2
476	Water-Soluble Derivatives of Octanuclear Iron-Oxo-Pyrazolato Complexes; An Experimental and Computational Study. <b>2012</b> , 2012, 3704	6
475	Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. <b>2012</b> , 30, 1132-7	8
474	Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. <b>2012</b> , 30, 1621-7	193
473	A shortened docetaxel desensitization protocol for use in special cases. <b>2012</b> , 26, 391-3	1
472	Review of hypersensitivity reactions to antineoplastic agents. <b>2012</b> , 36, 148-58	8
471	Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. <b>2012</b> , 424, 58-66	57
470	Synthesis and characterization of a novel polydepsipeptide contained tri-block copolymer (mPEG-PLLA-PMMD) as self-assembly micelle delivery system for paclitaxel. <b>2012</b> , 430, 282-91	37
469	Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor. <b>2012</b> , 45, 320-9	32
468	Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation. <b>2012</b> , 47, 179-89	97
467	Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. <b>2012</b> , 159, 14-26	564
466	Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. <b>2012</b> , 158, 386-92	105

465	Polyelectrolyte multilayer nanoshells with hydrophobic nanodomains for delivery of Paclitaxel. <b>2012</b> , 159, 403-412	35
464	Taxol alleviates 2-methoxyestradiol-induced endothelial permeability. <b>2012</b> , 56, 56-63	7
463	Non-haematopoietic toxicity of anthracyclines is more favourable than that of taxanes: experience from Nairobi. <b>2012</b> , 4, 3-8	
462	Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. <b>2012</b> , 69, 457-65	30
461	A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis. <b>2012</b> , 30, 236-48	55
460	The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. <b>2013</b> , 30, 2050-62	32
459	Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer. <b>2013</b> , 69, 1739-46	30
458	Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. <b>2013</b> , 166, 66-74	93
457	Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. <b>2013</b> , 88, 504-13	74
456	Prodrugs as self-assembled hydrogels: a new paradigm for biomaterials. <b>2013</b> , 24, 1174-82	59
455	Cubic magnetically guided nanoaggregates for inhalable drug delivery: in vitro magnetic aerosol deposition study. <b>2013</b> , 14, 977-93	5
454	Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives. <b>2013</b> , 454, 653-9	9
453	Paclitaxel loaded carrier based biodegradable polymeric implants: Preparation and in vitro characterization. <b>2013</b> , 21, 85-91	35
452	Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery. <b>2013</b> , 24, 1840-9	38
451	Selective tissue distribution and long circulation endowed by paclitaxel loaded PEGylated poly( $\epsilon$ -caprolactone-co-L-lactide) micelles leading to improved anti-tumor effects and low systematic toxicity. <b>2013</b> , 456, 101-12	29
450	Strategies to address low drug solubility in discovery and development. <b>2013</b> , 65, 315-499	992
449	Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment. <b>2013</b> , 454, 435-43	40
448	Optimization of parameters for preparation of docetaxel-loaded PLGA nanoparticles by nanoprecipitation method. <b>2013</b> , 33, 754-758	13

447	A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel. <b>2013</b> , 31, 616-22	15
446	Efficacy of combined therapy with paclitaxel and low-level ultrasound in human chronic myelogenous leukemia cell line K562. <b>2013</b> , 21, 874-84	10
445	A reconstituted "two into one" thermosensitive hydrogel system assembled by drug-loaded amphiphilic copolymer nanoparticles for the local delivery of paclitaxel. <b>2013</b> , 1, 552-563	44
444	Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. <b>2013</b> , 24 Suppl 5, v6-12	22
443	A critical review of lipid-based nanoparticles for taxane delivery. <b>2013</b> , 334, 157-75	127
442	Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2013</b> , 83, 266-74	5-7 57
441	Structure and aggregation proclivity of C12E3 in aqueous solution. <b>2013</b> , 410, 1-8	3
440	Paclitaxel-loaded polymeric micelle (230 mg/m <sup>2</sup> ) and cisplatin (60 mg/m <sup>2</sup> ) vs. paclitaxel (175 mg/m <sup>2</sup> ) and cisplatin (60 mg/m <sup>2</sup> ) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial. <b>2013</b> , 14, 275-82	17
439	Short-term outcomes of albumin-bound paclitaxel (abraxane)-containing chemotherapy in patients with advanced gastric cancer: a report of 14 cases. <b>2013</b> , 12, 30-34	2
438	Tissue distribution and pharmacokinetics evaluation of DOMC-FA micelles for intravenous delivery of PTX. <b>2013</b> , 21, 137-45	7
437	Small molecule, big difference: the role of water in the crystallization of paclitaxel. <i>Journal of Pharmaceutical Sciences</i> , <b>2013</b> , 102, 674-83	3-9 9
436	Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines. <b>2013</b> , 31, 1261-9	24
435	Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. <b>2013</b> , 454, 354-66	52
434	Facile preparation of paclitaxel loaded silk fibroin nanoparticles for enhanced antitumor efficacy by locoregional drug delivery. <b>2013</b> , 5, 12638-45	75
433	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. <b>2013</b> , 81, 97-101	34
432	Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. <b>2013</b> , 334, 245-52	60
431	Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. <b>2013</b> , 168, 88-102	283
430	A cell-targeted photodynamic nanomedicine strategy for head and neck cancers. <b>2013</b> , 10, 1988-97	50

429	Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. <b>2013</b> , 447, 94-101	168
428	Highly efficient loading of amorphous paclitaxel in mesoporous hematite nanorods and their in vitro antitumor activity. <b>2013</b> , 1, 1687-1695	8
427	Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. <b>2013</b> , 334, 338-45	174
426	Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. <b>2013</b> , 34, 3795-806	65
425	Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade. <b>2013</b> , 10, 2071-8	26
424	Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene. <b>2013</b> , 2, 172-85	41
423	Chapter 1:Targeted Drug Delivery in Oncology: Current Paradigm and Challenges. <b>2013</b> , 1-19	1
422	Mechanistic study of the covalent loading of paclitaxel via disulfide linkers for controlled drug release. <b>2013</b> , 29, 734-43	46
421	A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline. <b>2013</b> , 9, 176-81	9
420	Targeted drug delivery for cancer therapy. <b>2013</b> , 31-56	4
419	Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?. <b>2013</b> , 2013, 905091	47
418	Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. <b>2013</b> , 68, 853-61	77
417	Taxol(®)-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor(®) EL. <b>2013</b> , 8, 1127-35	21
416	Antimicrotubule Agents. <b>2013</b> , 208-214	1
415	Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies. <b>2013</b> , 23, 1318-25	9
414	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <b>2013</b> , 5, 125-35	19
413	Tumor Targeting via Integrin Ligands. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 222	5:3 164
412	Buckyosomes: New Nanocarriers for Anticancer Drugs. <b>2013</b> , 2013, 390425	1

411	Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. <b>2013</b> , 2013, 720858	42
410	Conventional Cancer Treatment. <b>2013</b> ,	6
409	Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer. <b>2014</b> , 25, 130-5	9
408	Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. <b>2014</b> , 21, e630-41	45
407	Presentation and management of docetaxel-related adverse effects in patients with breast cancer. <b>2014</b> , 6, 253-9	103
406	Enhanced brain delivery of lamotrigine with Pluronic(®) P123-based nanocarrier. <b>2014</b> , 9, 3923-35	32
405	Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. <b>2014</b> , 7, 187-92	20
404	A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. <b>2014</b> , 11, 479-87	16
403	Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. <b>2014</b> , 21, e691-703	25
402	Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?. <b>2014</b> , 14, 792	2
401	Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer. <b>2014</b> , 49, 425-31	4
400	Paclitaxel and trastuzumab for breast cancer. <b>2014</b> , 49, 338-44	1
399	Paclitaxel, Carboplatin, and trastuzumab. <b>2014</b> , 49, 913-9	1
398	Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients. <b>2014</b> , 19, 823-8	10
397	WITHDRAWN: Nanocochleates derived from nanoliposomes for paclitaxel oral use: Preparation, characterization, in vitro anticancer testing, bioavailability and biodistribution study in rats. <b>2014</b> ,	3
396	Enhanced antitumor efficacy of vitamin E TPGS-emulsified PLGA nanoparticles for delivery of paclitaxel. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2014</b> , 123, 716-23	6 35
395	Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer. <b>2014</b> , 44, 208-13	6
394	Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel). <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 177	5-3 5

393	Hyaluronic Acid Bioconjugates for the Delivery of Bioactive Molecules. <b>2014</b> , 6, 346-369		169
392	nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. <b>2014</b> , 14, 129-41		13
391	Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. <b>2014</b> , 25, 488-94		122
390	nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. <b>2014</b> , 40, 614-25		31
389	Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. <b>2014</b> , 89, 62-72		34
388	Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model. <b>2014</b> , 31, 983-91		17
387	Design, synthesis, and functionalization of nanomaterials for therapeutic drug delivery. <b>2014</b> , 811, 157-82		4
386	The synthesis of novel taxoids for oral administration. <b>2014</b> , 22, 194-203		13
385	Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier. <b>2014</b> , 16, 114-24		24
384	Designing protein-based biomaterials for medical applications. <b>2014</b> , 10, 1542-57		105
383	pH and glutathion-responsive hydrogel for localized delivery of paclitaxel. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2014</b> , 116, 247-56	6	25
382	Self-assembled chitosan-ceramide nanoparticle for enhanced oral delivery of paclitaxel. <b>2014</b> , 31, 3019-30		21
381	Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells. <b>2014</b> , 11, 1906-18		34
380	Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform. <b>2014</b> , 460, 131-43		145
379	Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif. <b>2014</b> , 15, 4326-35		18
378	Deoxycholic acid-modified chitoooligosaccharide/mPEG-PDLLA mixed micelles loaded with paclitaxel for enhanced antitumor efficacy. <b>2014</b> , 475, 60-8		31
377	Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses. <i>Immunology and Allergy Clinics of North America</i> , <b>2014</b> , 34, 565-96, viii	3-3	24
376	The drug discovery by nanomedicine and its clinical experience. <b>2014</b> , 44, 515-25		68

375	Dendrimer-TPGS mixed micelles for enhanced solubility and cellular toxicity of taxanes. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2014</b> , 121, 461-8	6	63
374	Taxol, Taxoids, and Related Taxanes. <b>2014</b> , 127-180		2
373	Development and characterization of stabilized double loaded mPEG-PDLLA micelles for simultaneous delivery of paclitaxel and docetaxel. <b>2014</b> , 40, 860-8		12
372	Drug-induced morphology switch in drug delivery systems based on poly(2-oxazoline)s. <b>2014</b> , 8, 2686-96		104
371	Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. <b>2014</b> , 14, 451		17
370	Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology. <b>2014</b> , 7, 119-121		
369	Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. <b>2014</b> , 28, 133-44		32
368	Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity. <b>2014</b> , 9, 156		9
367	PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel. <b>2014</b> , 11, 2807-14		25
366	EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma. <b>2014</b> , 35, 4133-45		53
365	Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. <b>2014</b> , 176, 76-85		76
364	Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics. <b>2014</b> , 71, 34-57		62
363	A novel aqueous parenteral formulation of docetaxel using prodrugs. <b>2014</b> , 462, 1-7		16
362	Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. <b>2014</b> , 32, 89-96		28
361	Paclitaxel-loaded trimethyl chitosan-based polymeric nanoparticle for the effective treatment of gastroenteric tumors. <b>2014</b> , 32, 1481-8		22
360	Biosafe nanoscale pharmaceutical adjuvant materials. <b>2014</b> , 10, 2393-419		16
359	nab-Paclitaxel dose and schedule in breast cancer. <b>2015</b> , 17, 81		16
358	Preparation and characterization of amphiphilic calixarene nanoparticles as delivery carriers for paclitaxel. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2015</b> , 63, 180-6	1.9	16

- 357 Reinvention of chemotherapy: drug conjugates and nanoparticles. **2015**, 27, 232-42 12
- 356 Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). **2015**, 62, 1214-21 27
- 355 Nanosomal Paclitaxel Lipid Suspension Demonstrates Higher Response Rates Compared to Paclitaxel in Patients with Metastatic Breast Cancer. **2015**, 07,
- 354 Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. **2015**, 9, 2189-99 30
- 353 Molecular Inclusion Complexes of  $\beta$ Cyclodextrin Derivatives Enhance Aqueous Solubility and Cellular Internalization of Paclitaxel: Preformulation and Assessments. **2015**, 2, 8 8
- 352 Albumin-bound paclitaxel in solid tumors: clinical development and future directions. **2015**, 9, 3767-77 132
- 351 Polymer-Drug Conjugates for Anticancer Drug Delivery. **2015**, 32, 215-45 16
- 350 Characterization of the host-guest complex of a curcumin analog with  $\beta$ Cyclodextrin and  $\beta$ Cyclodextrin-gemini surfactant and evaluation of its anticancer activity. **2015**, 10, 503-15 7
- 349 CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come. **2015**, 21, 1975-7 2
- 348 Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma. **2015**, 11 4
- 347 Delivery of paclitaxel using PEGylated graphene oxide as a nanocarrier. **2015**, 7, 1355-63 118
- 346 Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies. **2015**, 69, 51-60 42
- 345 Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors. **2015**, 23, 67-78 7
- 344 Nanotechnological carriers for cancer chemotherapy: the state of the art. *Colloids and Surfaces B: Biointerfaces*, **2015**, 126, 631-48 6 179
- 343 Evaluation and management of hypersensitivity reactions to chemotherapy agents. **2015**, 91, 145-50 12
- 342 Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer. **2015**, 14, 1075-84 68
- 341 Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles. **2015**, 12, 1230-41 40
- 340 Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel. **2015**, 483, 38-48 53



339	A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro. <i>Journal of Pharmaceutical Sciences</i> , <b>2015</b> , 104, 165-77	3.9	20
338	Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel. <b>2015</b> , 8, 201-218		70
337	Optimization of drug loading to improve physical stability of paclitaxel-loaded long-circulating liposomes. <b>2015</b> , 25, 308-15		15
336	Local delivery of paclitaxel in the treatment of peripheral arterial disease. <b>2015</b> , 45, 333-45		37
335	Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2015</b> , 96, 96-105 <sup>5-7</sup>		28
334	Redox/pH stimuli-responsive biodegradable PEGylated P(MAA/BACy) nanohydrogels for controlled releasing of anticancer drugs. <b>2015</b> , 484, 47-55		27
333	Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer. <b>2015</b> , 9, 1822-1826		12
332	Non-Biological Complex Drugs. <b>2015</b> ,		6
331	Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit non-small-cell lung cancer. <b>2015</b> , 492, 141-51		23
330	Clinical Translation of Nanomedicine. <b>2015</b> , 115, 11147-90		494
329	Nanoparticle Albumin-Bound Anticancer Agents. <b>2015</b> , 335-354		2
328	Recent progress in biomedical applications of Pluronic (PF127): Pharmaceutical perspectives. <b>2015</b> , 209, 120-38		200
327	Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin. <b>2015</b> , 25, 42-8		16
326	An insight into cochleates, a potential drug delivery system. <b>2015</b> , 5, 81188-81202		30
325	Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model. <b>2015</b> , 15, 317		8
324	A7RC peptide modified paclitaxel liposomes dually target breast cancer. <b>2015</b> , 3, 1545-54		63
323	Nanoscale Drug Delivery Systems: A Current Review on the Promising Paclitaxel Formulations for Future Cancer Therapy. <b>2015</b> , 10, 1530004		9
322	Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. <b>2015</b> , 76, 699-712		65

321	Variable association of complement activation by rituximab and paclitaxel in cancer patients in vivo and in their screening serum in vitro with clinical manifestations of hypersensitivity: a pilot study. <b>2015</b> , 7,	8
320	Engineered in-situ depot-forming hydrogels for intratumoral drug delivery. <b>2015</b> , 220, 465-475	99
319	Effect of sucrose as a lyoprotectant on the integrity of paclitaxel-loaded liposomes during lyophilization. <b>2015</b> , 25, 270-8	25
318	Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles. <b>2015</b> , 478, 617-24	72
317	Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals. <b>2015</b> , 41, 1343-52	15
316	Discovering and Developing Molecules with Optimal Drug-Like Properties. <b>2015</b> ,	5
315	Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy. <b>2015</b> , 32, 1002-16	58
314	Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2015</b> , 49, 177-91	12.3 84
313	Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution. <b>2016</b> , 44, 350-5	17
312	. <b>2016</b> ,	10
311	A novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. <b>2016</b> , 11, 2119-31	13
310	Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies. <b>2016</b> , 7, 268-75	10
309	Paclitaxel. <b>2016</b> , 445-452	
308	Nanobiomaterials in cancer therapy. <b>2016</b> , 57-89	5
307	Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial. <b>2016</b> , 12, 289-99	9
306	Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors. <b>2016</b> , 36, 399-409	18
305	Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes. <b>2016</b> , 17, 367-374	7
304	Effect of surface ligand density on cytotoxicity and pharmacokinetic profile of docetaxel loaded liposomes. <b>2016</b> , 11, 655-661	22

303	Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2016</b> , 104, 251-9	5-7	27
302	Nanotechnology for the delivery of phytochemicals in cancer therapy. <b>2016</b> , 34, 343-353		93
301	Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?. <i>Therapeutic Advances in Medical Oncology</i> , <b>2016</b> , 8, 209-219	5-9	22
300	Targeted Delivery of Docetaxel by Use of Transferrin/Poly(allylamine hydrochloride)-functionalized Graphene Oxide Nanocarrier. <b>2016</b> , 8, 13282-93		66
299	Supramolecular nanocapsules from the self-assembly of amphiphilic calixarene as a carrier for paclitaxel. <b>2016</b> , 40, 9923-9929		23
298	Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-positive breast cancer cells. <b>2016</b> , 513, 543-553		21
297	A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel. <b>2016</b> , 43, 282-291		24
296	Enhanced Antiglioblastoma Efficacy of Neovasculature and Glioma Cells Dual Targeted Nanoparticles. <b>2016</b> , 13, 3506-3517		20
295	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. <b>2016</b> , 111, 577-591		26
294	Impact of surfactant treatment of paclitaxel nanocrystals on biodistribution and tumor accumulation in tumor-bearing mice. <b>2016</b> , 237, 168-76		34
293	Chemotherapy-mediated pain and peripheral neuropathy: impact of oxidative stress and inflammation. <b>2016</b> , 367-388		1
292	Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity. <b>2016</b> , 514, 150-159		49
291	Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. <b>2016</b> , 6, 20160054		8
290	Nanoparticle Albumin-Bound Paclitaxel (Abraxane®). <b>2016</b> , 101-119		19
289	Nursing Care of Patients Undergoing Chemotherapy Desensitization: Part I. <b>2016</b> , 20, 29-32		1
288	Design, synthesis, and evaluation of water-soluble morpholino-decorated paclitaxel prodrugs with remarkably decreased toxicity. <b>2016</b> , 26, 3598-602		1
287	A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. <b>2016</b> , 101, 296-309		115
286	Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. <b>2016</b> , 78, 1101-1111		16

285	Development of a validated LC-APCI-MS/MS method to study the plasma and tumor distribution of CHO-PTX intravenous lipid emulsion. <b>2016</b> , 117, 532-43		2
284	Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2016</b> , 141, 74-82	6	78
283	PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. <b>2016</b> , 500, 345-59		25
282	Oncologic Emergencies. <b>2016</b> ,		1
281	Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. <b>2016</b> , 56, 162-171		18
280	Nanotechnology and traditional medicine: challenges and opportunities. <b>2016</b> , 7, 157-62		
279	Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. <b>2016</b> , 137, 1154-1164.e12		62
278	Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study. <b>2016</b> , 156, 125-34		30
277	Chemotherapy-Related Emergencies. <b>2016</b> , 253-271		
276	Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. <b>2016</b> , 98, 113-33		70
275	Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs. <b>2016</b> , 33, 18-39		156
274	Safe dose reduction of steroid pre-medication for docetaxel in head and neck neoplasm treatment. <b>2016</b> , 136, 177-80		2
273	Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization. <b>2016</b> , 26, 175-87		22
272	D-amino acid-containing supramolecular nanofibers for potential cancer therapeutics. <b>2017</b> , 110-111, 102-111		54
271	A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. <b>2017</b> , 22, 129-e8		12
270	Clinical application of polymeric micelles for the treatment of cancer. <b>2017</b> , 1, 1485-1501		94
269	Encapsulating an Immunosuppressant Enhances Tolerance Induction by Siglec-Engaging Tolerogenic Liposomes. <b>2017</b> , 18, 1226-1233		23
268	Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?. <b>2017</b> , 80, 65-69		7

267	Paclitaxel: What has been done and the challenges remain ahead. <b>2017</b> , 526, 474-495	205
266	PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application. <b>2017</b> , 260, 46-60	238
265	Lipid-Based Nanocarriers in Cancer Therapy. <b>2017</b> , 51-66	1
264	Self-assembly of glutamic acid linked paclitaxel dimers into nanoparticles for chemotherapy. <b>2017</b> , 27, 2493-2496	11
263	Rationale for Cardio-Oncology Units. <b>2017</b> , 70, 583-589	3
262	Ferritin Decorated PLGA/Paclitaxel Loaded Nanoparticles Endowed with an Enhanced Toxicity Toward MCF-7 Breast Tumor Cells. <b>2017</b> , 28, 1283-1290	29
261	Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents. <b>2017</b> , 14, 1217-1226	25
260	Magnetite nanocluster and paclitaxel-loaded charge-switchable nanohybrids for MR imaging and chemotherapy. <b>2017</b> , 5, 849-857	14
259	Management of Hypersensitivity Reactions to Taxanes. <i>Immunology and Allergy Clinics of North America</i> , <b>2017</b> , 37, 679-693	3-3 33
258	Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies. <b>2017</b> , 145, 242-255	26
257	A conjugation of stearic acid to apotransferrin, fattigation-platform, as a core to form self-assembled nanoparticles: Encapsulation of a hydrophobic paclitaxel and receptor-driven cancer targeting. <b>2017</b> , 41, 222-230	13
256	Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer. <b>2017</b> , 27, 1794-1801	5
255	Fundamentos de las unidades de cardio-oncología. <b>2017</b> , 70, 583-589	8
254	Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. <b>2017</b> , 34, 151	20
253	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <b>2017</b> , 22, 1301-1308	10
252	Cytotoxic Chemotherapy. <b>2017</b> , 220-235	
251	Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer. <b>2017</b> , 80, 469-478	13
250	Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. <b>2017</b> , 28, iv100-iv118	49

249	Hidden Causes of Anaphylaxis. <b>2017</b> , 17, 44		2
248	Inhibition of breast cancer metastasis by paclitaxel-loaded pH responsive poly(E-amino ester) copolymer micelles. <b>2017</b> , 12, 147-164		18
247	Paclitaxel pre-medication: A comparison of two steroid pre-medication protocols. <i>Journal of Oncology Pharmacy Practice</i> , <b>2017</b> , 23, 491-495	1.7	3
246	Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2017</b> , 150, 89-97	6	29
245	Design, synthesis and evaluation of multi-functional tLyP-1-hyaluronic acid-paclitaxel conjugate endowed with broad anticancer scope. <b>2017</b> , 156, 97-107		24
244	Nanomedicine-based paclitaxel induced apoptotic signaling pathways in A562 leukemia cancer cells. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2017</b> , 149, 16-22	6	13
243	Impact of Dendrimers on Solubility of Hydrophobic Drug Molecules. <b>2017</b> , 8, 261		105
242	Nanomedicinal products: a survey on specific toxicity and side effects. <b>2017</b> , 12, 6107-6129		33
241	Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo. <b>2017</b> , 12, 1499-1514		21
240	Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <b>2017</b> , 108, 987-994		13
239	Plitidepsin: design, development, and potential place in therapy. <b>2017</b> , 11, 253-264		46
238	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. <b>2018</b> , 18, 435-446		9
237	Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. <b>2018</b> , 126, 186-200		53
236	A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. <b>2018</b> , 91, 86-91		31
235	Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. <b>2018</b> , 29, 1220-1226		24
234	Remotely Phototriggered, Transferrin-Targeted Polymeric Nanoparticles for the Treatment of Breast Cancer. <b>2018</b> , 94, 765-774		19
233	Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 2471-2477	3.9	9
232	Hierarchically Self-Assembled Supramolecular Host-Guest Delivery System for Drug Resistant Cancer Therapy. <b>2018</b> , 19, 1926-1938		41

231	Assessment of Antihistamines and Corticosteroids as Premedication in Rapid Drug Desensitization to Paclitaxel: Outcomes in 155 Procedures. <b>2018</b> , 6, 1356-1362	14
230	Self-stabilized, hydrophobic or PEGylated paclitaxel polymer prodrug nanoparticles for cancer therapy. <b>2018</b> , 9, 687-698	19
229	Special Issue in Honor of Professor Susan Band Horwitz. <b>2018</b> , 81, 449-450	2
228	Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer. <b>2018</b> , 26, 66-74	29
227	Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry. <i>Pharmaceutical Development and Technology</i> , <b>2018</b> , 23, 67-75	3-4 1
226	Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions. <b>2018</b> , 6, 1266-1273.e2	14
225	Chemotherapy Allergy. <b>2018</b> , 197-210	
224	Novel sulforaphane-enabled self-microemulsifying delivery systems (SFN-SMEDDS) of taxanes: Formulation development and in vitro cytotoxicity against breast cancer cells. <b>2018</b> , 536, 187-198	30
223	Extraction protocol and liquid chromatography/tandem mass spectrometry method for determining micelle-entrapped paclitaxel at the cellular and subcellular levels: Application to a cellular uptake and distribution study. <b>2018</b> , 1072, 347-354	3
222	Characteristics, Properties and Analytical Methods of Paclitaxel: A Review. <b>2018</b> , 48, 110-118	44
221	Poly(2-oxazoline)-Pterostilbene Block Copolymer Nanoparticles for Dual-Anticancer Drug Delivery. <b>2018</b> , 19, 103-111	22
220	Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma. <b>2018</b> , 19,	21
219	Pulmonary Toxicities of Anticancer Treatment. <b>2018</b> , 201-215	
218	Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. <b>2018</b> , 9, 1184	12
217	Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. <b>2018</b> , 15, 4835-4842	29
216	Docetaxel-Loaded Hyaluronic Acid-Cathepsin B-Cleavable-Peptide-Gold Nanoparticles for the Treatment of Cancer. <b>2018</b> , 15, 4668-4676	19
215	Current taxane formulations and emerging cabazitaxel delivery systems. <b>2018</b> , 11, 5193-5218	22
214	Comparative effectiveness of early-line -paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis. <b>2018</b> , 10, 249-256	13

213	Ginsenoside C-Mx Isolated from Noto Ginseng Stem-leaf Ginsenosides Attenuates Ultraviolet B-mediated Photoaging in Human Dermal Fibroblasts. <b>2018</b> , 94, 1040-1048	11
212	Educational Intervention to Improve Delirium Recognition by Nurses. <b>2018</b> , 27, 270-278	12
211	Preparation, characterization, and pharmacokinetics of liposomal docetaxel for oral administration. <b>2018</b> , 41, 765-775	16
210	Low-power and low-drug-dose photodynamic chemotherapy via the breakdown of tumor-targeted micelles by reactive oxygen species. <b>2018</b> , 286, 240-253	14
209	Biomimetic nano-surfactant stabilizes sub-50 nanometer phospholipid particles enabling high paclitaxel payload and deep tumor penetration. <b>2018</b> , 181, 240-251	5
208	Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol. <b>2018</b> , 53, 1105-1117	11
207	The anticancer efficacy of paclitaxel liposomes modified with low-toxicity hydrophobic cell-penetrating peptides in breast cancer: an and evaluation.. <b>2018</b> , 8, 24084-24093	12
206	Syntheses of C-ring modified dehydroabietyl amides and their cytotoxic activity. <i>European Journal of Medicinal Chemistry</i> , <b>2018</b> , 156, 861-870	6.8 10
205	Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects. <b>2018</b> , 12, 40-52	20
204	PTX-loaded three-layer PLGA/CS/ALG nanoparticle based on layer-by-layer method for cancer therapy. <b>2018</b> , 29, 1566-1578	16
203	Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration. <b>2018</b> , 13, 719-731	19
202	New Treatment Modalities for the Management of Peritoneal Metastases. <b>2018</b> , 469-506	3
201	Physicochemical, Pharmacokinetic, and Toxicity Evaluation of Methoxy Poly(ethylene glycol)-Poly(D,L-Lactide) Polymeric Micelles Encapsulating Alpinumisoflavone Extracted from Unripe Fruit. <b>2019</b> , 11,	15
200	Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. <b>2019</b> , 14, 1323-1341	44
199	The Involvement of the RhoA/ROCK Signaling Pathway in Hypersensitivity Reactions Induced by Paclitaxel Injection. <b>2019</b> , 20,	3
198	The Application of Biomaterials in the Treatment of Platinum-Resistant Ovarian Cancer. <b>2019</b> , 14, 1810-1827	3
197	Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article. <b>2019</b> , 311-312, 125-137	42
196	Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. <b>2019</b> , 12, 855-861	22



195	Desensitization for Allergic Reactions to Chemotherapy. <b>2019</b> , 60, 119-125	13
194	Evaluation of the Biological Behavior of a Gold Nanocore-Encapsulated Human Serum Albumin Nanoparticle (Au@HSANP) in a CT-26 Tumor/Ascites Mouse Model after Intravenous/Intraperitoneal Administration. <b>2019</b> , 20,	11
193	Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. <b>2019</b> , 110, 448-459	3
192	Breakthrough reactions during rapid drug desensitization: Clinical outcome and risk factors. <b>2019</b> , 123, 48-56.e1	5
191	In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations. <b>2019</b> , 565, 219-226	24
190	Paclitaxel interaction with cucurbit [7]uril and acyclic Cucurbit[4]uril nanocontainers: A computational approach. <b>2019</b> , 90, 210-218	2
189	Vielfältige Physik. <b>2019</b> ,	
188	Chitosan-based nanoparticles: promising biomedical applications in specific drug delivery and targeting. <b>2019</b> , 215-257	1
187	Biofunctional core-shell polypyrrole-polyethylenimine nanocomplex for a locally sustained photothermal with reactive oxygen species enhanced therapeutic effect against lung cancer. <b>2019</b> , 14, 1575-1585	20
186	Comparison of paclitaxel solid dispersion and polymeric micelles for improved oral bioavailability and in vitro anti-cancer effects. <b>2019</b> , 100, 247-259	30
185	Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel. <b>2019</b> , 20,	17
184	Production of LMWH-conjugated core/shell hydrogels encapsulating paclitaxel for transdermal delivery: In vitro and in vivo assessment. <b>2019</b> , 128, 610-620	5
183	Poly(ethylene glycol)-block-poly(D,L-lactic acid) micelles containing oligo(lactic acid)-paclitaxel prodrug: In Vivo conversion and antitumor efficacy. <b>2019</b> , 298, 186-193	19
182	Natural product drug delivery: A special challenge?. <b>2019</b> , 58, 157-187	10
181	Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye. <b>2019</b> , 24, e149-e153	3
180	Preparation and anticancer activity evaluation of self-assembled paclitaxel conjugated MPEG-PCL micelles on 4T1 cells. <b>2019</b> , 71, 369-377	9
179	Paclitaxel formulation with stable sustained-release behavior and its biological safety evaluation. <b>2019</b> , 62, 1151-1159	7
178	Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. <b>2019</b> , 47, 268-277	12

177	Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study. <b>2019</b> , 7, 990-997		20
176	Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. <b>2019</b> , 293, 21-35		32
175	Adverse drug reactions of anticancer drugs derived from natural sources. <b>2019</b> , 123, 522-535		41
174	Exploring an interesting dual functionality of anacardic acid for efficient paclitaxel delivery in breast cancer therapy. <b>2019</b> , 14, 57-75		6
173	Potential of Chitosan and its derivatives for controlled drug release applications [A review]. <b>2019</b> , 49, 642-659		64
172	Development of a Subcellular Semimechanism-Based Pharmacokinetic/Pharmacodynamic Model to Characterize Paclitaxel Effects Delivered by Polymeric Micelles. <i>Journal of Pharmaceutical Sciences</i> , <b>2019</b> , 108, 725-731	3.9	4
171	Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. <b>2019</b> , 16, 69-78		184
170	D-Optimal Optimization and Data-Analysis Comparison Between a DoE Software and Artificial Neural Networks of a Chitosan Coating Process onto PLGA Nanoparticles for Lung and Cervical Cancer Treatment. <b>2019</b> , 14, 206-220		4
169	A One-Bag Rapid Desensitization Protocol for Paclitaxel Hypersensitivity: A Noninferior Alternative to a Multi-Bag Rapid Desensitization Protocol. <b>2020</b> , 8, 696-703		11
168	In vivo antitumour properties of tribenzyltin carboxylates in a 4T1 murine metastatic mammary tumour model: Enhanced efficacy by PLGA nanoparticles. <b>2020</b> , 142, 105140		5
167	Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. <b>2020</b> , 1873, 188319		22
166	Metal-shell nanocapsules for the delivery of cancer drugs. <b>2020</b> , 567, 171-180		12
165	From lanthanide-mediated, high-precision group transfer polymerization of Michael-type monomers, to intelligent, functional materials. <b>2020</b> , 122, 109385		2
164	Mitotic Poisons in Research and Medicine. <b>2020</b> , 25,		13
163	Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer. <b>2020</b> , 86, 487-495		
162	Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. <b>2020</b> , 20, 1111		2
161	Overcoming the blood-brain barrier by Annexin A1-binding peptide to target brain tumours. <b>2020</b> , 123, 1633-1643		7
160	Physicochemical, Pharmacokinetic, and Toxicity Evaluation of Soluplus Polymeric Micelles Encapsulating Fenbendazole. <b>2020</b> , 12,		10

159	Exploiting nanoscale cooperativity for precision medicine. <b>2020</b> , 158, 63-72		8
158	Use of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) via Multiple Imaging Modalities and Modifications to Reduce Cytotoxicity: An Educational Review. <b>2020</b> , 1, 105-135		13
157	Transdermal Delivery Systems of Natural Products Applied to Skin Therapy and Care. <b>2020</b> , 25,		10
156	Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status Report. <b>2020</b> , 80, 399-409		1
155	Triple-negative breast cancer molecular subtyping and treatment progress. <b>2020</b> , 22, 61		249
154	Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study. <b>2020</b> , 12, 77-85		2
153	Liquid chromatography tandem mass spectrometry method for determination of fulvestrant in rat plasma and its application to pharmacokinetic studies of a novel fulvestrant microcrystal. <b>2020</b> , 34, e4912		0
152	Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis. <b>2020</b> , 15, 1731-1743		10
151	Research progress on nanotechnology for delivery of active ingredients from traditional Chinese medicines. <b>2020</b> , 8, 6333-6351		12
150	Chemotherapy-induced pneumonitis associated with transient CA 15-3 elevation. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 1750-1753	1.7	1
149	Interpenetrating Polymer Network: Biomedical Applications. <b>2020</b> ,		2
148	Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer. <b>2020</b> , 21, 1091-1102	9	
147	Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. <b>2020</b> , 145, 1082-1123		182
146	Label-Free Quantitative Proteomic Profiling of LAD2 Mast Cell Releasates Reveals the Mechanism of Tween-80-Induced Anaphylactoid Reaction. <b>2020</b> , 14, e1900065		1
145	Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer. <b>2020</b> , 43, 663-668		2
144	Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine. <b>2020</b> , 371-404		4
143	Rapid Self-Assembly of Polymer Nanoparticles for Synergistic Codelivery of Paclitaxel and Lapatinib via Flash NanoPrecipitation. <b>2020</b> , 10,		13
142	Drug delivery systems to prevent peritoneal metastasis after surgery of digestives or ovarian carcinoma: A review. <b>2021</b> , 592, 120041		1

141	Click activated prodrugs against cancer increase the therapeutic potential of chemotherapy through local capture and activation. <b>2021</b> , 12, 1259-1271		10
140	New PTX-HS15/T80 Mixed Micelles: Cytotoxicity, Pharmacokinetics and Tissue Distribution. <b>2021</b> , 22, 56		1
139	Evaluation of novel paclitaxel-loaded NO-donating polymeric micelles for an improved therapy for gastrointestinal tumor. <b>2021</b> , 45, 13763-13774		0
138	Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy. <b>2021</b> , 22,		3
137	Comparative study of oral and IV dexamethasone premedication in the prevention of docetaxel induced allergic reactions. <i>Journal of Oncology Pharmacy Practice</i> , <b>2022</b> , 28, 96-100	1.7	
136	Advances in engineering of low molecular weight hydrogels for chemotherapeutic applications. <b>2021</b> , 16, 024102		3
135	Annexin A1-Binding Carbohydrate Mimetic Peptide Targets Drugs to Brain Tumors.		
134	Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model. <b>2021</b> , 174, 494-501		5
133	Paclitaxel loading in cationic liposome vectors is enhanced by replacement of oleoyl with linoleoyl tails with distinct lipid shapes. <b>2021</b> , 11, 7311		4
132	The added value of H <sub>2</sub> antagonists in premedication regimens during paclitaxel treatment. <b>2021</b> , 124, 1647-1652		3
131	Opportunities and challenges of fatty acid conjugated therapeutics. <b>2021</b> , 236, 105053		7
130	Design and Development of D-α-Tocopheryl Polyethylene Glycol Succinate--Poly(ε-Caprolactone) (TPGS--PCL) Nanocarriers for Solubilization and Controlled Release of Paclitaxel. <b>2021</b> , 26,		1
129	Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study. <b>2021</b> , 15, 162		0
128	A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer. <b>2021</b> , 334, 335-352		3
127	Assessing taxane-associated adverse events using the FDA adverse event reporting system database. <b>2021</b> , 134, 1471-1476		3
126	Breast cancer: Muscarinic receptors as new targets for tumor therapy. <b>2021</b> , 12, 404-428		1
125	Enhanced Paclitaxel Efficacy to Suppress Triple-Negative Breast Cancer Progression Using Metronomic Chemotherapy with a Controlled Release System of Electrospun Poly-d-l-Lactide-Co-Glycolide (PLGA) Nanofibers. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
124	Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics. <b>2021</b> , 13,		15

123	Solubilization of Paclitaxel by Self-Assembled Amphiphilic Phospholipid-Mimetic Polymers with Varied Hydrophobicity. <b>2021</b> , 13,		0
122	Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3583-3590	2.2	4
121	Prevention of Drug Hypersensitivity Reactions: Prescreening and Premedication. <b>2021</b> , 9, 2958-2966		1
120	Severe anaphylaxis caused by intravenous anti-cancer drugs. <b>2021</b> , 10, 7174-7183		1
119	Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response. <b>2021</b> , 24, 103170		1
118	Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. <b>2021</b> , 26, 927-933		1
117	Preparation, Characterization, and In-Vitro Assessment of Calixarene Nanovesicles: A Supramolecular Based Nano-Carrier for Paclitaxel Drug Delivery. <b>2021</b> , 55, 570		4
116	New chemotherapeutic agents for breast cancer. <b>1994</b> , 74, 1164-1176		11
115	Cardiac Complications. <b>2006</b> , 1420-1426		1
114	Current Endeavors for Enhancing Efficacy of Paclitaxel for Treatment of Glioblastoma. <b>2010</b> , 299-323		1
113	Intraperitoneal taxol. <b>1996</b> , 81, 1-5		9
112	New antineoplastic agents in lung cancer 1988-1993. <b>1994</b> , 323-347		2
111	Discovery Formulations: Approaches and Practices in Early Preclinical Development. <b>2015</b> , 49-94		6
110	Pharmaceutics of Nanoparticles. <b>2016</b> , 219-238		1
109	Microtubule Stabilizing Agents in Clinical Oncology. <b>2008</b> , 395-419		2
108	Clinical pharmacology and use of microtubule-targeting agents in cancer therapy. <b>2007</b> , 137, 209-34		11
107	Drug Desensitizations in the Management of Allergy and Anaphylaxis to Chemotherapeutic Agents and Monoclonal Antibodies. <b>2011</b> , 297-311		2
106	Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. <b>2019</b> , 110, 448-459		2

105	Self-assembled poly(butadiene)-b-poly(ethylene oxide) polymersomes as paclitaxel carriers. <b>2007</b> , 23, 278-85	70
104	Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles. <b>1997</b> , 20, 373-5	28
103	Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies. <b>1998</b> , 21, 129-34	4
102	An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. <b>1998</b> , 21, 416-9	101
101	Anaphylaxis from intraperitoneal infusion of cisplatin: a case report. <b>1999</b> , 22, 172-3	7
100	Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. <b>2000</b> , 23, 349-52	13
99	Evaluation of lipid-coated microbubbles as a delivery vehicle for Taxol in brain tumor therapy. <b>1997</b> , 40, 1260-6; discussion 1266-8	30
98	Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report. <b>2020</b> , 99, e22814	2
97	20th-Century Advances in Drug Therapy in Oncology Part II. <b>2000</b> , 40, 1079-1092	3
96	Taxanes as a first-line systemic treatment in metastatic breast cancer. <b>2013</b> , 17 Suppl, 15-21	4
95	Taxol and Its Analogs. <b>2005</b> ,	5
94	The severe adverse reaction to vitamin k1 injection is anaphylactoid reaction but not anaphylaxis. <b>2014</b> , 9, e90199	27
93	Adding vitamin E-TPGS to the formulation of Genexol-PM: specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantly. <b>2015</b> , 10, e0120129	26
92	Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs. <b>2014</b> , 19, 269-80	3
91	Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer. <b>2015</b> , 20, 407-17	10
90	Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials. <b>2017</b> , 8, 72950-72958	14
89	Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer. <b>2020</b> , 15, 8151-8166	10
88	Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles. <b>2019</b> , 26, 5278-5292	3

87	Immunological and Toxicological Considerations for the Design of Liposomes. <b>2020</b> , 10,	71
86	Efficacy and safety of nanosomal docetaxel lipid suspension-based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study. <b>2020</b> , 20, 344	0
85	Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. <b>2021</b> , 42, 3	3
84	Polyamide/Poly(Amino Acid) Polymers for Drug Delivery. <b>2021</b> , 12,	0
83	Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start. <b>2022</b> , 40, 11.e9-11.e15	1
82	Relief of paclitaxel-induced arthralgia and myalgia with oral prednisone in patients with ovarian cancer. <b>2002</b> , 14, 29-31	
81	Chemotherapy of Ovarian Cancer. <b>2003</b> , 487-503	
80	Allergische Reaktionen. <b>2006</b> , 1947-1952	
79	nab-Paclitaxel: Reducing Toxicity Using Albumin-Bound Particles as the Carrier for Paclitaxel. <b>2007</b> , 251-258	
78	Nano-Carriers of Drugs and Genes for the Treatment of Restenosis. <b>2007</b> , 235-269	
77	Paclitaxel and Gemcitabine (PG) for Advanced Breast Cancer. <b>2007</b> , 42, 510-516	
76	Monitoring of Leukocyte Counts to Help Ensure Proper Use of Anticancer Drugs in Patients with Solid Tumors. <b>2008</b> , 34, 320-327	1
75	DRUGS USED IN CANCER CHEMOTHERAPY. <b>2010</b> , 1-229	
74	Examination on the Effect of Docetaxel Dilution Concentration on the Hypersensitivity Revelation Rate. <b>2012</b> , 38, 547-558	
73	Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics. 438-469	
72	Acute Myocardial Infarction in Patient With Triple Negative Breast Cancer After Paclitaxel Infusion: A Case Report. <b>2014</b> , 5, 108-111	3
71	Chemotherapeutic Engineering. <b>2014</b> , 21-80	
70	Chemotherapeutic Engineering. <b>2014</b> , 139-154	

- 69 In vitro and in vivo Investigation on PLGA-PEG Nanoparticles for Controlled and Sustained Small Molecule Chemotherapy. **2014**, 157-178
- 68 Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination. **1991**, 441-452
- 67 New Chemotherapeutic Agents: A Selection of Some of the Most Promising New Drugs. **1993**, 335-346
- 66 T. **1994**, 765-1129
- 65 Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer. **1995**, 215-223
- 64 The European-Canadian study of paclitaxel in ovarian cancer. High vs low dose; long vs short infusion. **1995**, 225-229
- 63 Taxoids and Multidrug Resistance. **1995**, 153-171
- 62 Prophylaxe und Behandlung spezieller Nebenwirkungen von Zytostatika. **1998**, 93-119
- 61 Hematological Disorders. **1999**, 263-294
- 60 Drug-induced Pulmonary Disorders. **1999**, 403-436 2
- 59 Soluble Guanylyl Cyclase (sGC) in Mechanisms of Hypotensive and Antiaggregatory Effects Induced by Teraphtal (TP, sodium salt 4,5-carboxyphthalocyanin-cobalt). **2016**, 9, 138-147 1
- 58 Distinct Solubility and Cytotoxicity Regimes of Paclitaxel-Loaded Cationic Liposomes at Low and High Drug Content Revealed by Kinetic Phase Behavior and Cancer Cell Viability Studies.
- 57 Polymere Nanopartikel als Formulierung für die Krebstherapie. **2019**, 283-292
- 56 Efficacy and safety of Nab-paclitaxel in breast cancer: a meta-analysis.
- 55 Nab-paclitaxel in Treatment of Metastatic Breast Cancer. **2019**, 2, 12-18 1
- 54 Begleittherapie bei 5-Fluorouracil, Capecitabine, Taxanen, Irinotecan und Platinsalzen. **2020**, 1-6
- 53 History of Paclitaxel and Oral Paclitaxel Clinical Data and Future. **2020**, 41, 260-263
- 52 Bioprotein Based IPN Nanoparticles as Potential Vehicles for Anticancer Drug Delivery: Fabrication Technology. **2020**, 183-203



51	Structural and Functional Dynamics of Lysosomal Cysteine Proteases with Particular Reference to Cathepsin B and Cathepsin H. <b>2020</b> , 391-424		1
50	Dermatological Toxicities of Chemotherapy. <b>2020</b> , 73-92		
49	Paclitaxel hypersensitivity. <b>2020</b> , 3, 419		1
48	Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma. <b>2020</b> , 13, 14		
47	A Multicenter Retrospective Study to Evaluate Safety and Efficacy of Tocopheryl Polyethylene Glycol Succinate Docetaxel in Various Cancers. <b>2020</b> , 41, 543-546		
46	Enhanced Loading of Paclitaxel in Cationic Liposomes by Replacement of Oleoyl with Linoleoyl Lipid Tails with Benefits in Cancer Therapeutics from In Vitro Studies.		
45	Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. <b>2004</b> , 115, 395-404; discussion 404		12
44	Taxol: an important new drug in the management of epithelial ovarian cancer. <b>1991</b> , 64, 583-90		30
43	Validated HPLC Method for the Determination of Paclitaxel-related Substances in an Intravenous Emulsion Loaded with a Paclitaxel-Cholesterol Complex. <b>2013</b> , 75, 672-9		3
42	Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis?. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 10781552211050084	1.7	
41	Emerging nanotechnology based combination therapies of taxanes for multiple drug-resistant cancers. <i>Pharmaceutical Development and Technology</i> , <b>2021</b> , 1-13	3-4	0
40	Hipersensibilidad a carboplatino y paclitaxel: revisión y recomendaciones clínicas. <b>2002</b> , 4, 68-71		
39	Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study).. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211061989	5.4	
38	A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMEDI-F1 study.. <i>Supportive Care in Cancer</i> , <b>2022</b> , 30, 3389	3.9	1
37	Protein Nanoparticles: Uniting the Power of Proteins with Engineering Design Approaches.. <i>Advanced Science</i> , <b>2022</b> , e2104012	13.6	5
36	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.. <i>Pharmacology &amp; Therapeutics</i> , <b>2022</b> , 236, 108108	13.9	4
35	Desensitization for the prevention of drug hypersensitivity reactions.. <i>Korean Journal of Internal Medicine</i> , <b>2022</b> ,	2.5	2
34	The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives.. <i>Archives of Gynecology and Obstetrics</i> , <b>2022</b> , 1	2.5	0

33	Atopy, allergen sensitization and development of hypersensitivity reactions to paclitaxel.. <i>Journal of Oncology Pharmacy Practice</i> , <b>2022</b> , 10781552221080415	1.7	
32	Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review.. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2022</b> , 1	12.3	1
31	Boosting the Therapeutic Efficacy of Discoidal Nanoconstructs against Glioblastoma with Rationally Designed PEG-Docetaxel Conjugates.. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2022</b> ,	5.7	1
30	Paclitaxel-loaded PEGylated Cationic Lipid Nanodiscs and Small Liposomes with Protruding Brush Conformation PEG-chains Show Tumor Penetration and Proapoptotic Caspase-3 Activation.		
29	Emerging Challenges and Innovations in Surfactant-Mediated Stabilization of Biologic Formulations. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> ,	3.9	1
28	Characterization of Novel Paclitaxel Nanoparticles Prepared by Laser Irradiation.. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2022</b> , 70, 269-276	1.9	1
27	Natural saponin and cholesterol assembled nanostructures as the promising delivery method for saponin.. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2022</b> , 214, 112448	6	
26	Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 772920	5.3	2
25	Data_Sheet_1.PDF. <b>2018</b> ,		
24	Population Pharmacokinetics for Oral Paclitaxel in Patients with Advanced/Metastatic Solid Tumors.. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2022</b> ,	4.5	
23	Histamine-2(H ) Antagonists can be safely removed from standard Paclitaxel Pre-medication regimens.. <i>British Journal of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	
22	Support Drugs. <b>2022</b> , 339-369		
21	Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.. <i>Journal of Nanobiotechnology</i> , <b>2022</b> , 20, 233	9.4	o
20	Influence of sodium bicarbonate in conversion of intermolecular to intramolecular hydrogen bonding to induce stiffness in MC-based nanovesicular formulation of paclitaxel. <i>Journal of Sol-Gel Science and Technology</i> ,	2.3	
19	Liposomal formulations for lung cancer treatment in the last two decades: a systematic review. <i>Journal of Cancer Research and Clinical Oncology</i> ,	4.9	o
18	Drug Desensitization in Immediate-Type Hypersensitivity. <b>2022</b> , 109-126		
17	H2 blockers in the prevention of paclitaxel-related hypersensitivity reaction. <i>The National Medical Journal of India</i> , 34, 350-351	0.4	
16	Sex Differences in Taxane Toxicities. <i>Cancers</i> , <b>2022</b> , 14, 3325	6.6	o

15	Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study. <i>Pharmacology Research and Perspectives</i> , <b>2022</b> , 10,	3.1	0
14	Basophil Activation Test as a Biomarker for Taxanes Anaphylaxis. <i>Frontiers in Allergy</i> , 3,	0	0
13	Complete regression of xenografted breast tumors by dextran-based dual drug conjugates containing paclitaxel and docosahexaenoic acid. <i>European Journal of Medicinal Chemistry</i> , <b>2022</b> , 240, 114567	6.8	1
12	ANAPHYLAXIS IN THE ELDERLY. <i>Immunology and Allergy Clinics of North America</i> , <b>1993</b> , 13, 627-646	3.3	
11	Current development of cabazitaxel drug delivery systems.		0
10	Multifunctional Polymeric Nanocarriers for Targeted Brain Delivery. <b>2022</b> , 259-305		0
9	Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation.		0
8	Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics. <b>2023</b> , 101591		2
7	Inhalable CAR-T Cell-Derived Exosomes as Paclitaxel Carriers for Treating Lung Cancer.		0
6	A Ferroptosis-Inducing and Leukemic Cell-Targeting Drug Nanocarrier Formed by Redox-Responsive Cysteine Polymer for Acute Myeloid Leukemia Therapy. <b>2023</b> , 17, 3334-3345		0
5	The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer. <b>2023</b> , 11, 705		0
4	Fanatical Clout of Porous Carbon Materials A Peek in Therapeutics. <b>2023</b> , 841-883		0
3	Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.		0
2	Chemotherapy in Cutaneous Melanoma: Is There Still a Role?.		0
1	Research Progress of PSOX Chemotherapy Regimen in Gastric Cancer. <b>2023</b> , 13, 7659-7664		0